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6ABSTRACT
Osteoporosis is a common disease, which is caused by both genetic and en-
vironmental factors.  Osteoporosis increases the risk of fragility fractures, re-
duces quality of life, and raises mortality rates in affected individuals. Despite 
years of extensive genetic research, only a few clinically signiﬁcant underlying 
genes have been identiﬁed. These have been discovered by linkage analysis of 
families with extreme bone phenotypes. The numerous gene polymorphisms 
identiﬁed by genome-wide association studies have only modest effects on 
bone mineral density.  This suggests that the osteoporosis phenotype seen in 
the general population is probably due to complex inheritance, i.e. caused by 
many interacting genetic factors. 
The aim of this investigation was to examine young patients and families with 
early-onset osteoporosis in order to better deﬁne their clinical phenotype and 
to clarify their genetic predisposition. A cohort of 27 children with juvenile 
osteoporosis and 60 family members were assessed at the Hospital for Sick 
Children, Toronto, Canada. The majority of assessed children had at least one 
parent with low bone mineral density implying a strong heredity of the disor-
der. Certain polymorphisms (Q89R, V667M, N740N and A1330V) in the gene 
encoding for low density lipoprotein receptor-related protein 5 (LRP5) were 
shown to be over-represented in this cohort. 
Patients with a clinical diagnosis of osteoporosis-pseudoglioma syndrome 
(OPPG), a rare disease caused by biallelic mutations in LRP5, were screened and 
presented four new mutations affecting protein splicing along with the ﬁrst 
functional data on a splice site mutation in LRP5. 
Finnish families with many individuals suffering from osteoporosis were also 
assessed. In a family with early-onset osteoporosis, 11 of 19 examined family 
members were found to be affected. The clinical characteristics include sub-
optimal bone accrual in adolescence, severe osteoporosis in adulthood, pro-
gressive compression fractures of the vertebrae, and proneness to peripheral 
fractures. Histomorphometric analyses from four affected individuals also in-
dicated low-turnover bone metabolism. Two genomic regions (1p22.2-p21.1 
and 11q22.1-q22.3), which may contain their disease-causing genetic varia-
tions, were identiﬁed by microsatellite linkage analysis. The exons in the puta-
tive linkage areas were sequenced by target enrichment and next-generation 
sequencing, and three heterozygous non-synonymous variations were found 
in the genes encoding for BCAR3 (p.F6Y), MMP10 (p.R53K), and DYNC2H1 
(p.Q304L). These require further assessment to clarify their clinical signiﬁcance. 
In another family, the rare syndrome of Calvarial Doughnut Lesions (CDL) was 
diagnosed in a young girl with osteoporosis and severe glaucoma. Her father 
and paternal grandmother were also affected. A thorough characterization of 
ABSTRACT
7the clinical and bone histomorphometric features of the condition is provided 
here. A role for LRP5 has been excluded in the pathogenesis of CDL, given that 
no mutations have been found in this gene to correspond with the clinical 
cases studied.
 This thesis provides new data regarding the clinical features and genetic back-
ground of bone weakness in children. The impact of these discovered genetic 
defects requires further elucidation in future studies. 
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1. INTRODUCTION
Osteoporosis is a genetic or acquired bone disorder, which has serious conse-
quences for both affected patients and the community. Osteoporosis-related 
bone fragility causes signiﬁcant morbidity, mortality, and increased health care 
expenditures. The most common forms of osteoporosis are age- and sex-hor-
mone related, or iatrogenic e.g. due to corticosteroid treatment. In patients 
without obvious external causes of bone weakness, hereditary factors play a 
signiﬁcant role: the heredity of osteoporosis between ﬁrst-degree relatives is 
high (Stewart & Ralston, 2000). Early identiﬁcation of patients at risk is crucial. 
Potent drugs for the prevention of fragility fractures and related complications 
exist, but the challenge is to diagnose the bone weakness before it becomes 
symptomatic and to choose the most effective remedy. Identifying the underly-
ing genetic variations and understanding their functional impact may enable 
clinicians to identify individuals at high risk of sustaining osteoporotic fractures 
and researchers to develop new therapeutic agents. Thus far, genome-wide 
association studies in large populations have failed to identify clinically signiﬁ-
cant genomic variations. Findings regarding some genes and pathways have 
been replicated, but in many studies the results have diverged. Hereto discov-
ered variations have only modest effects on bone density. The few known sig-
niﬁcant genes linked to osteoporosis have been pinpointed by linkage studies 
of affected families, one example being the low density lipoprotein receptor-
related protein 5 (LRP5) (Gong et al., 2001).  This gene functions in the so-called 
Wnt pathway, which is an extensively studied but still not completely under-
stood pathway affecting bone accrual and renewal (Westendorf et al., 2004).
This study focuses on monogenic forms of osteoporosis and the role of LRP5 
in early-onset disease. Children and families exhibiting signiﬁcant osteoporot-
ic bone phenotypes were examined with the goal of identifying clinical and 
genetic patterns, and ultimately new genetic variations, behind this complex 
disease. 
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2. REVIEW OF THE LITERATURE
2.1 BONE HEALTH AND OSTEOPOROSIS
2.1.1 Bone health and normal structure 
Bones form the supportive backbone of the body, functioning as the main 
storage of minerals and as the center for hematopoiesis. Bones are composed 
of bone tissue and of bone marrow, endosteum, periosteum, nerves, blood 
vessels, and cartilage. Bone tissue, a dense mineralized connective tissue, is 
mainly composed of calcium hydroxyapatite, which gives bones their rigidity. 
The elasticity of bones is provided by the organic components, mainly type I 
collagen ﬁbers. This combination of hard mineral and ﬂexible collagen makes 
bone hard and strong without being brittle. 
There are two types of bone tissue, compact and trabecular, which have identi-
cal biology but different micro-architecture. The main part of bone mass is con-
tained in compact bone, which is of low porosity and forms the hard, smooth 
bone surface. The interior is ﬁlled with trabecular bone bridges, hematopoietic 
bone marrow, and fatty tissue. Trabecular bone is of high porosity and since it 
contains 90% of the total bone surface, it constitutes the metabolically active 
area. 
The bone-forming osteoblasts and osteocytes are mononucleate cells descend-
ing from osteoprogenitor cells of mesenchymal stem cell origin (Figure 1). They 
communicate with other osteocytes and osteoblasts through long cytoplasmic 
processes, which also function as sensory receptors for mechanical loading. 
Bone resorption occurs at bone surfaces by osteoclasts, which are large, multi-
nucleated cells of monocyte stem cell origin (Figure 1). Osteoclasts resorb bone 
by secreting enzymes and by phagocytic mechanisms. (Coe et al., 2002)
Bone remodeling is the coordinated process of bone resorption followed by 
new bone formation for the maintenance of calcium homeostasis and for dam-
age repair. Bone modeling, on the other hand, is an uncoupled process of bone 
formation and degradation, mostly regulated by mechanical forces. Bone mod-
eling is necessary to shape the skeleton during growth and to maintain bone 
shape and mass. (Giustina et al., 2008) Bone is continuously built and degrad-
ed simultaneously and these two processes, together termed bone turnover, 
are tightly interconnected to maintain calcium homeostasis and bone mass. 
Systemic hormone levels affect bone turnover both through direct binding to 
receptors and indirectly by affecting local cytokine production in a complex 
manner (Table I). Bone turnover is mainly orchestrated by osteoblasts that se-
crete cytokines which either stimulate or inhibit osteoclast differentiation and 
activity. The most important regulatory pathway in bone metabolism is the 
REVIEW OF THE LITERATURE
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RANK/RANKL/OPG-pathway, which involves the osteoclastic receptor for re-
ceptor activator of nuclear factor-kappaB (RANK) and its ligands: RANK-ligand 
(RANKL) and the decoy ligand osteoprotegerin (OPG); both secreted by osteob-
lasts (Hofbauer et al., 2000). High levels of RANKL shift bone turnover towards 
resorption, while an increase in OPG diminishes bone loss and enables an in-
crease in bone mass. The main activator of osteoblast activity is the canonical 
Wnt pathway (Glass et al., 2005), which is presented in detail in Chapter 2.3.
Bone formation and resorption occur continuously throughout life. Bone mass 
increases in childhood and adolescence, reaching a plateau level in early adult-
hood. Up to 90% of this peak bone mass is acquired before the age of 18, 
and over 25% of adult total bone mass is accrued during the 2 years around 
peak bone mineral density (BMD) velocity (Bailey et al., 1999). After puberty, 
bone mass accumulation decreases rapidly (Theintz et al., 1992) and the bone 
mass remains rather stable between ages 20 to 30. Thereafter a slow age- and 
hormone-related loss of bone mass can be observed, rapidly accelerating after 
menopause in women and 5-10 years later in men.
REVIEW OF THE LITERATURE
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Figure 1. Bone forming cells, osteoblasts and osteocytes, are of mesenchymal stem 
cell origin. Osteoblasts produce the collagenous matrix, or the osteoid, and the 
enzyme alkaline phosphatase, which enables mineralization of the osteoid. As 
the mineralized matrix hardens into new bone, osteoblasts become entrapped 
and develop into osteocytes, which are mature bone cells responsible for matrix 
maintenance and calcium homeostasis. Osteoblasts and osteocytes communicate 
through cytoplasmic processes and control the bone turnover rate in a paracrine 
fashion by secreting cytokines which affect the differentiation and activity of bone 
osteoclasts and osteoblasts. 
REVIEW OF THE LITERATURE
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Table I. The hormonal regulation of bone turnover is complex and involves many 
interacting factors. The main hormonal regulators of bone turnover (by endocrine 
signaling) are presented, along with a selected number of local cytokines repre-
senting autocrine and paracrine signaling in bone. 
OB, osteoblast; OC, osteoclast.
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2.1.2 Assessment of bone health
There are many means to assess bone health. I) Bone turnover can be estimated 
with blood and urine markers reﬂecting the bone formation and resorption 
rates. II) Bone mass can be measured with methods estimating areal or volu-
metric BMD. III) Assessment of bone quality and micro-architecture by histo-
morphometric studies from bone samples provides the most exact informa-
tion on bone strength and turnover. In the clinical setting, assessment of bone 
health becomes relevant if an individual presents with recurrent fractures, or 
suffers from medical conditions or uses certain medications known to cause de-
terioration of bone health. Some of the methods mentioned below are mainly 
utilized in research settings.
Biomarkers of bone health
During bone formation and resorption, protein cleavage products and enzymes 
are released into the circulation and excreted into the urine. These can be as-
sessed by standardized laboratory methods available at most hospitals. The 
markers are not valid in the diagnosis of osteoporosis, but provide additional 
information on the rate of bone remodeling and can be used as a complement 
to BMD measurements, e.g. in the follow-up of osteoporosis treatments. The 
most commonly used markers for bone formation, reﬂecting osteoblast activ-
ity, are all measured from serum. Deposition of the organic matrix is reﬂected 
by procollagen type I C- and N-terminal peptides (PICP, PINP). Bone-speciﬁc 
alkaline phosphatase (BALP) relates to the organization and calciﬁcation of the 
matrix, and the calcium-binding non-collagenous protein osteocalcin (OCN) is 
maximally expressed during mineralization of the matrix. (Caulﬁeld and Reitz, 
2004; Hauschka et al., 1989; Lewiecki, 2010) Bone resorption can be assessed 
by measurement of collagen degradation products: C-terminal telopeptide of 
type I collagen (ICTP) from serum and N-telopeptide of type I collagen (NTX) 
from serum or urine. Collagen degradation also releases pyridinium cross-
links, which can be measured from urine as deoxypyridinoline (DPD). Tartrate-
resistant acid phosphatase isoform 5b (TRAP-5b) is an enzyme released by 
osteoclasts which dissolves the mineral matrix, and is measured from serum 
samples (Caulﬁeld and Reitz, 2004). The reference values of these markers are 
age- and sex speciﬁc (Seibel, 2005, 2006). 
Measurement of bone mass and mineral density 
The golden standard for bone health assessment is BMD measurement by du-
al-energy X-ray absorptiometry (DXA), which is the base for the diagnosis of 
osteoporosis according to the guidelines of the World Health Organization 
(WHO, 1994). DXA is the most commonly used tool for assessing BMD due to 
its wide availability and low radiation dose. DXA measures bone mineral con-
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tent (BMC) and bone area, and these are expressed as areal BMD (aBMD) in 
grams per square centimeter. The result is compared with the mean aBMD 
of young healthy adults, and the deviation from this mean value in standard 
deviation (SD) units is designated the T-score. When the measured BMD value 
is compared with gender-, age-, and ethnicity-matched controls, the differ-
ence in BMD expressed in SDs is called Z-score. In children and adolescents only 
the Z-score should be used, and a diagnosis of osteoporosis should not be set 
in children based on BMD measurements alone (Specker and Schoenau, 2005; 
Lewiecki et al., 2008; Rizzoli, 2010).  
Areal BMD does not fully take bone size into account. A more reliable means 
for assessing BMD is therefore a volumetric measurement. Quantitative com-
puted tomography (QCT) from the spine or from peripheral measuring sites 
(from the radius, tibia or femur) provides three-dimensional data on bone min-
eral density, geometry, and size, as well as allows for distinction between the 
cortical and trabecular bone compartments. The radiation dose for spine meas-
urements is much higher than in DXA, but peripheral measurements provide 
reliable results with lower radiation (Specker and Schoenau, 2005).
Quantitative ultrasound (QUS) measures the attenuation of the ultrasound 
beam when it passes through bone. Reference values for calcaneal and phalan-
geal measurements are available, but only calcaneal measurements are validat-
ed in clinical use for osteoporosis management.  QUS can be used for prelimi-
nary screening as the measuring device is portable, inexpensive, and there is no 
exposure to radiation. (Specker and Schoenau, 2005; Lewiecki et al., 2008) 
Assessment of bone histology
The most accurate quantitative information regarding bone micro-architecture 
and turnover is obtained by histomorphometric studies of bone biopsy speci-
mens. The sample specimen should be obtained from the anterior superior 
iliac spine by standardized methods and should be intact and transiliac, i.e. 
contain two cortices separated by trabecular bone. Histomorphometric analysis 
is helpful for both accurate diagnosis and treatment follow-up of metabolic 
bone diseases. It provides exact quantitative information on the amount and 
distribution of bone and bone cells in the sample. For assessment of dynamic 
bone parameters, such as mineral apposition rate and bone formation rate, a 
two-course per oral tetracycline labeling is required prior to the biopsy (Rauch, 
2003). The acquisition of a bone biopsy sample requires an invasive procedure 
and is therefore more sparingly used in the clinical setting. The biopsy sam-
ple can be scanned with micro-CT for three-dimensional ﬁne trabecular detail 
analysis.  Other alternatives for assessment of micro-architecture are high-res-
olution CT and magnetic resonance imaging (MRI), but these are used only in 
research settings due to cost, poor availability, and lack of consensus regarding 
analytic standards. (Grifﬁth and Genant, 2008) 
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2.1.3 Osteoporosis
Deﬁnition, prevalence and morbidity
Osteoporosis is a metabolic skeletal disorder, in which compromised bone 
strength predisposes an individual to a higher risk of fragility fractures. 
According to the WHO osteoporosis criteria, bone fragility arises from a de-
crease in bone mass and from micro-architectural deterioration without dis-
turbances in mineralization (WHO, 1994). Osteoporosis is the most common 
skeletal condition in the Western world; the lifetime risk of fractures associ-
ated with osteoporosis exceeds 40% in women and 20% in men (Kanis et al., 
2000). Approximately 10 million people in the United States are estimated to 
suffer from osteoporosis and 18 million more have osteopenia, or decreased 
BMD, yielding a prevalence of low bone mass exceeding 10% in the population 
(Osteoporosis prevention, 2001). The estimated annual ﬁnancial expenditures 
were estimated to $10-$15 billion in 2001 in the US, not including preventive 
care nor morbidity-related lost wages and productivity (Osteoporosis preven-
tion, 2001).
Apart from the ﬁnancial consequences, osteoporosis-related fractures cause a 
signiﬁcant decrease in the patients’ quality of life; this applies to both hip and 
vertebral fractures (Lips et al., 2005; Salafﬁ et al., 2007; Willig et al., 2001). In 
the majority of affected patients the condition permanently affects functional 
ability to carry out day-to-day chores, social activities, and interferes with fam-
ily relationships (Roberto, 2004). Two thirds of patients who have sustained 
a hip fracture never regain their pre-fracture level of function (Willig et al., 
2001). Sustaining fractures is also associated with excess mortality; the one-
year mortality after a hip fracture is 20% (Piirtola et al., 2008). 
Diagnosis 
The WHO deﬁnition of osteoporosis is only applicable to BMD measurements 
using DXA, and the diagnostic threshold values have been set according to 
data from postmenopausal women. The clinical diagnosis of osteoporosis is 
based on the T-score, with a T-score of less than -1.0 being deﬁned as osteopen-
ic and a T-score of less than -2.5 as osteoporotic (WHO, 1994). In healthy chil-
dren and adolescents, BMD increases continuously and varies with age, gender, 
height, skeletal maturation, and pubertal status. The measured BMD value is 
therefore compared with gender-, age-, and ethnicity-matched controls. Due 
to great individual variation in maturation during childhood and puberty, BMD 
should further be adjusted for skeletal maturity and/or height, as appropri-
ate (Specker and Schoenau, 2005; Gordon et al., 2008; Rizzoli, 2010). In young 
adults and children, Z-scores below -2.0 are considered “low bone mass for 
chronologic age” (Lewiecki et al., 2008).
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When examining a patient with suspected bone weakness, laboratory tests 
for parameters of calcium homeostasis, vitamin D levels, and speciﬁc tests to 
exclude causes of secondary osteoporosis, e.g. celiac disease antibodies and 
thyroid function markers, should be considered based on patient history and 
clinical ﬁndings. Bone turnover markers may be useful, e.g. in the follow-up of 
treatment response.  
Histomorphometric studies are mainly used in research settings, but can aid the 
clinician in the establishment of diagnosis and in treatment follow-up. Apart 
from quantitative information on the amount and distribution of bone and 
bone cells in the sample, they provide information on mineralization and bone 
turnover.
Etiology
Osteoporosis can occur in both sexes and at all ages, and is etiologically di-
vided into primary and secondary osteoporosis (Table II). The most common 
form of osteoporosis is age-related and strongly associated with the decrease 
of sex hormones in the elderly population. The most signiﬁcant risk factors for 
osteoporosis are female sex, high age, Caucasian race, low body mass index, 
estrogen deﬁciency, family history of bone fragility, history of previous frac-
tures, glucocorticoid therapy, and use of tobacco and alcohol (Kronenberg et 
al., 2008; Osteoporosis prevention, 2001; Sandhu and Hampson, 2011). 
Primary osteoporosis can arise due to; I) failure to achieve optimal peak bone 
mass in adolescence, II) excessive resorption of bone, or III) failure to adequate-
ly replace the resorbed bone, i.e. through a bone formation deﬁcit. With in-
creasing age and declining sex hormone levels, the bone resorption rate ex-
ceeds that of bone formation and a physiological rapid decline in BMD occurs 
in women after menopause and in men around the age of 60-65 years. After 
post-menopausal osteoporosis the most common cause of primary osteoporo-
sis is osteogenesis imperfecta (OI) caused by mutations in the genes coding for 
type I collagen and related peptides (Roughley et al., 2003; Rauch and Glorieux, 
2004). The typical features of OI are bone fragility with multiple peripheral and 
vertebral compression fractures, blue sclerae, excessive joint laxity, dentino-
genesis imperfecta, and hearing loss (Roughley et al., 2003). Other hereditary 
forms are known (summarized under Genetics of osteoporosis; Table III), but 
they are rare. There is strong evidence for signiﬁcant heredity in the remaining 
patients, but as the genetic background is unknown and some patients have 
no family background of bone disease, these cases are termed idiopathic.   
Secondary osteoporosis arises as a complication of many medical conditions 
and drugs, which can affect bone strength and predispose patients to fragil-
ity fractures (Table II). The most common form of secondary osteoporosis is 
connected to the long-term use of glucocorticoids, which causes a signiﬁcant 
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decrease in BMD even at low dosage (Laan et al., 1993). Other drugs affecting 
bone metabolism and strength include, for example, anticonvulsants, chemo-
therapeutic agents, heparin, glitazones, and gonadotropin-releasing hormone 
analogues (Kaufman et al., 2008; Kiratli et al., 2001). Osteoporosis can be a 
feature of certain genetic and hereditary disorders as well as many endocrine, 
nutritional or gastrointestinal, hematopoeitic, connective tissue, and severe 
chronic disorders. (Kaufman et al., 2008; Kronenberg et al., 2008). 
Adolescence is the crucial time for bone mass accrual. After the age of 20 
years, only approximately 5-10% of peak bone mass is acquired. Regarding 
peak bone mass, the strongest predictor is heredity (Bonjour et al., 2007), but 
it is also affected by factors such as nutrition, physical activity, and illnesses 
(Bailey et al., 1999; Stewart & Ralston 2000). Even if these non-genetic factors 
were transient, they can affect bone health in later life (Rizzoli et al., 2010). 
Conversely, by ensuring adequate calcium and vitamin D intake in children, a 
higher peak bone mass can be achieved with possible beneﬁts in adulthood 
(Bonjour et al., 2001). In many patients, bone weakness may become sympto-
matic in late adulthood despite the fact that their bone structure may have 
been suboptimal since adolescence. Based on a computer simulation, the onset 
of osteoporosis in adulthood may be postponed by 13 years if the individual 
has achieved a 10% higher peak bone mass than the average (Hernandez et 
al., 2003). This shows that the optimal time to intervene for the prevention of 
osteoporosis is, in fact, during adolescence.  
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Table II. Causes of osteoporosis.
Primary
Aging
Genetic / hereditary
Idiopathic
Secondary
Endocrine disorders 
 Acromegaly
 Cushing’s syndrome
 Diabetes mellitus (type 1)
 Hyperparathyroidism
 Hyperthyroidism
 Hypogonadism 
Nutritional, gastrointestinal and malabsorption disorders
 Chronic pancreatitis
 Cystic ﬁbrosis
 Gastrectomia, bariatric surgery
 Hepatobiliary disease
 Inﬂammatory bowel disease
 Malabsorption syndromes (e.g. coeliac disease)
 Pernicious anaemia
 Total parenteral nutrition
 Vitamin and mineral deﬁciency
Connective tissue disorders 
 (Osteogenesis Imperfecta, often included in primary osteoporosis)
 Ehlers-Danlos syndrome
 Homocystinuria
 Marfan’s syndrome
Hematopoietic disorders
 Haemochromatosis
 Leukemias, lymphomas
 Mastosytosis
 Myeloproliferative disorders
 Plasma cell dyscrasias
Others
 Alcoholism 
 Chronic obstructive pulmonary disease 
 End-stage renal insufﬁciency
 Hypercalciuria
 Hyperhomocysteinaemia
 Immobilization
 Medications
 Neoplastic diseases
 Post-transplantation
 Rheumatoid arthritis
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2.2 GENETICS
2.2.1 The human genome and its variation
Normal structure of genes
The human genome consists of 22 pairs of autosomal chromosomes and one 
pair of sex chromosomes; XX for females and XY for males. All cells contain the 
identical genetic code inherited from the parents. The chromosomes contain 
the genetic code as densely packed deoxyribonucleic acid (DNA) in helical coils 
built up from a chain of four bases: adenosine (A), thymine (T), guanine (G), 
and cytosine (C). These bases form pairs; A-T and G-C, and therefore DNA is 
double-stranded. Human DNA contains approximately 3 billion base pairs, in 
addition to a small amount of maternally inherited mitochondrial DNA. 
The genetic code is divided into gene-containing coding regions or exons, and 
non-coding regions or introns. Exons contain the information for protein syn-
thesis and introns can contain regulators of gene transcription such as promot-
ers, response elements, enhancers, and silencers.
For intracellular production of proteins, the DNA is ﬁrst copied, transcribed, 
in the nucleus into single-stranded messenger ribonucleic acid (mRNA), which 
after exiting the nucleus binds to small organelles in the cytoplasm called ri-
bosomes. Here the mRNA is spliced in such a way that sections unnecessary 
for the production of proteins, the introns, are spliced off and translation into 
proteins occurs only from the genomic code contained by the exons. In the 
translation from mRNA to proteins, one triplet of bases encodes for an amino 
acid most frequently starting from the amino acid methionine (Met), which 
functions as the start codon, and ending in a stop codon. 
After translation, the protein can be cleaved, modiﬁed by addition of e.g. li-
pids, sugar chains, or phosphate groups, and it coils into a three-dimensional 
structure, which often is crucial for the correct function of the protein. Proteins 
have multiple functions and can serve as building material, hormones, enzymes, 
receptors, and transcription factors in the body. (Strachan et al., 1996)
Genetic variation
The most common form of genetic variation is a single-base variation, or single 
nucleotide polymorphism (SNP), which occurs in approximately 1:1000 bases 
(Ng et al., 2008). Less than 1% of SNPs are thought to be of functional signiﬁ-
cance. A SNP which does not result in the alteration of an amino acid is called 
synonymous, and if the encoded amino acid changes, the variation is called 
non-synonymous. If the non-synonymous variation alters the function of the 
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protein, it is called a missense mutation. In a nonsense mutation the change of 
nucleotide introduces a premature stop codon resulting in premature termina-
tion of translation. 
The additions or removal of nucleotides from the genetic sequence are called 
insertions or deletions. Due to the three-base reading frame in protein transla-
tion, a single insertion or deletion can change the reading frame of the coding 
sequence (a so-called frameshift mutation) resulting in the complete alteration 
of the subsequent protein or in the introduction of a premature stop codon.    
SNPs, insertions, and deletions can also change the way in which the mRNA 
is spliced at the ribosomes, especially if the genomic variation occurs at the 
exonic or intronic bases adjacent to the splice site at the beginning, or at the 
end, of an exon. These changes are called splice site mutations and can cause 
the exclusion of a complete exon, the activation of secondary splice sites, and 
the change of the reading frame of the sequence.
Genetic variation also includes repetitions of parts of the sequence, sometimes 
multiple repetitions of only two or three nucleotides (so-called microsatellites) 
to large duplications. Chromosomal changes also include inversions (the rota-
tion of a sequence segment) and translocations (the exchange of sequence 
segments between chromosomes). The impact of the genetic variation varies 
vastly with the site it affects: a mutation caused by the change of a single base 
can cause a lethal phenotype, while large deletions can remain asymptomatic 
(Strachan et al., 1996; Brown, 2003). The majority of genetic variations in hu-
mans are functionally neutral (Ng et al., 2008). Missense mutations, and even 
nonsense and frameshift mutations, in functional genes may be of no clinical 
relevance due to multiple gene copies and gene redundancy based on evolu-
tion (Ng et al., 2008).  
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2.2.2 Genetic screening and mapping
When looking for disease-causing genetic changes, the mode of inheritance 
must be taken into account. According to Mendelian laws, a dominant disease 
is inherited as a single defective allele from one parent, whereas a recessive 
disease requires the inheritance of a faulty allele from both parents. As the 
presumption is that Mendelian inheritance is caused by a single causative gene 
or variation, this mode of inheritance is called simple. In complex inheritance 
there are multiple loci affecting the phenotype, each often with a small ef-
fect. Diseases of Mendelian inheritance are often rare, possibly due to poorer 
reproductive ﬁtness. Common diseases, such as type-2 diabetes, are often due 
to complex inheritance with a multitude of genetic variations rendering the 
individual susceptible to or protected from the disease.    
Traditionally, the heredity of disorders has been investigated through twin 
studies. Since environmental factors are shared among twins, and monozy-
gotic twins share 100% and dizygotic twins 50% of their genotype, the envi-
ronmental effect vs. heritability for a certain phenotype can be assessed. 
Due to the different modes of inheritance, different approaches to identify 
the underlying genetic changes are necessary. In diseases with Mendelian in-
heritance, pedigree studies with linkage analysis are useful. The genome is 
screened using markers, e.g. SNPs or microsatellite repeats. As nearby markers 
are often inherited together in “blocks”, a marker inheritance pattern can be 
created revealing a possible linkage between disease phenotypes and certain 
genetic markers. For statistical analysis, a logarithmic odds score (LOD score) is 
calculated, which is equal to the logarithm to base 10 of the ratio of the “prob-
ability of linkage” to the “probability of non-linkage” of the marker with re-
spect to the investigated phenotype. A LOD score of ≥ 3 (which corresponds to 
the odds of 1000:1) is generally regarded as acceptable evidence for linkage. 
Linkage analysis on the association of the phenotype to single microsatellite 
markers is done by two-point LOD-score analysis, whereas a multi-point LOD-
score analysis takes into account whether multiple adjacent markers link to the 
investigated phenotype. The strength of linkage analysis is that monogenic 
inherited diseases can be found based on a limited number of affected indi-
viduals, provided that they are related. The draw-back is that after the identi-
ﬁcation of linkage regions, pin-pointing the underlying gene and its mutation 
can demand time-consuming sequencing of large genetic regions.
If the individuals are not related, the investigated phenotype can be caused 
by sequence variations in different genes in the genome, which renders the 
use of linkage analysis impossible. The approach taken is then “case vs. con-
trol”, where healthy controls should be genetically matched to the affected 
patients (i.e. chosen from the same population). Markers in candidate genes 
for a particular disease in candidate gene association studies or genome-wide 
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markers (common SNPs) in genome-wide association studies (GWAS) are ana-
lyzed. The frequency of these genetic markers is compared between cases and 
controls and if a difference in frequency between these groups is discovered, 
the marker is considered to be associated with the phenotype. The weakness 
of the candidate gene approach is that only selected parts of the genome are 
screened, and the valid selection of candidate genes can be demanding. As the 
cost of genome-wide studies has become manageable, the genome-wide ap-
proach has gained popularity. The draw-back of association studies, however, 
is that large numbers of both cases and controls are required to achieve suf-
ﬁcient statistical power. (Strachan et al., 1996; Brown, 2003)
Recently, the combination of next-generation sequencing, where large areas 
of the genome can be sequenced in one run, and the so-called target enrich-
ment, where speciﬁc regions of the genome are selected and enriched for 
sequencing, has enabled researchers to directly sequence e.g. large linkage 
areas or even all exons in the genome in a single run (Hodges et al., 2007). 
This new method will aid in identifying rare disease-causing genetic changes 
and, as the cost for the method falls, also by-pass the need for linkage and as-
sociation studies (Ng et al., 2009). The difﬁculty with this approach is ﬁltering 
the results. Based on the results from a whole-exome sequencing project, one 
healthy adult carried approximately 12500 coding variants which alter protein 
sequence. Of the over 10000 non-synonymous SNPs 7% were novel and over 
100 induced a premature stop codon. The screened individual carried over 700 
insertions or deletions in coding areas, of which half caused a frameshift of the 
reading frame. Singling out a disease-causing mutation from this amount of 
variations may prove to be an arduous task. (Ng et al., 2008) 
2.2.3 Genetics of osteoporosis 
Susceptibility genes for osteoporosis
Osteoporosis is a highly inherited trait; twin and family studies have revealed 
the heredity among ﬁrst-degree relatives to be from 50% to 80% (Howard et 
al., 1998; Stewart & Ralston 2000, Ralston et Crombrugghe 2006). The heredity 
of osteoporosis has traditionally been considered to be complex, with many 
predisposing factors together causing the phenotype. In segregation analyses 
of pedigrees with extreme BMD values, an estimated 16% of the variation of 
BMD is explained by monogenic traits and an additional 56% by residual poly-
genic effects. No evidence has been found to support an underlying aetiology 
of shared familial environmental effects in these studies (Spotila et al., 1996; 
Cardon et al., 2000, Deng et al., 2002). There are a few reports on dominantly 
inherited osteoporosis with high penetrance, but despite signiﬁcant and small 
linkage regions, the causative genes are yet to be identiﬁed in these pedigrees 
(Vidal et al., 2007; Willaert et al., 2008) with the exception of OI-causing muta-
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tions, some rare syndromes, and mutations in the genes encoding low density 
lipoprotein receptor-related protein (LRP) 5 and LRP6 (Gong et al., 2001; Mani 
et al., 2007). (Table III)
Interestingly, the underlying genetic predispositions for low BMD and increased 
fracture risk seem to diverge. A positive fracture history in family members cor-
relates with an individual’s risk for fragility fractures and micro-architectural 
deterioration in bone, but not always with the risk of low BMD (Deng et al.; 
Andrew et al., 2005; Genant et al., 2007; Sirola et al., 2008). Low BMD itself 
is a signiﬁcant risk factor for fragility fractures. The fracture risk in women 
increases 1.5- to 2.6-fold with a one SD decrease in BMD (Marshall et al., 1996) 
and in prepubertal children every one SD decrease in volumetric BMD (vBMD) 
increases the risk of fracture by 89% (Clark et al., 2006). Nevertheless, a BMD 
T-score below -2.5 explains only 10% to 44% of fragility fractures (Stone et al., 
2003). The genes predisposing to fractures are thus unlikely to play a direct 
etiological role in the development of low BMD in a large scale. This diver-
gence renders the genetic research of osteoporosis more challenging as the 
phenotypes overlap.
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Table III. Known forms of genetic/hereditary disorders with decreased bone min-
eral density, excluding bone fragility from bone mineralization defects and osteo-
petrosis.
OI: osteogenesis imperfecta; OPPG: osteoporosis-pseudoglioma syndrome; DGI: dentinogenesis imperfecta; 
AD: autosomal dominant; AR: autosomal recessive. Adapted and updated from Superti-Furga et al [2007]. 
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Results from linkage and association studies 
Numerous genome-wide linkage and association studies have been performed 
aiming at identifying loci that regulate BMD. The results from the most rel-
evant studies are summarized in Table IV (with data on the corresponding pub-
lications in Table V). Only few of the loci meet the criteria set for genome-wide 
signiﬁcance. 
Taking into account the large number of studies performed, a surprisingly low 
replication rate of susceptibility loci can be found. This may signify that the loci 
in different ethnic populations differ from each other. Many of the genes seem 
to regulate bone strength in a site- and gender-speciﬁc manner, and the genes 
that regulate peak bone mass acquisition differ from those affecting BMD in 
the elderly. There is also some evidence for a relation between osteoporosis 
susceptibility and parental imprinting of gene function, i.e. that the extent of 
gene expression depends upon the sex of the parent that transmits the gene 
(Duncan et al., 2003). Another possible explanation for the discrepant results is 
that many genetic variations with modest effects exist and that the variations 
interact, thereby making the statistical strength of genome-wide scans insuf-
ﬁcient for detection. 
The most signiﬁcant ﬁndings include variations in the genes encoding type I 
collagen (COL1A1 and COL1A2) and in genes of speciﬁc pathways regulating 
bone turnover. These pathways include  the Wnt pathway regulating bone for-
mation rate (described in more detail below) and the RANK-RANKL-signaling 
system regulating bone cell differentiation and bone resorption involving 
RANK, it’s ligand RANKL, and OPG; the decoy receptor of RANKL . In addi-
tion, receptors and enzymes related to estrogen and vitamin D affect bone 
strength in the general population. One pathway-based association study has 
also identiﬁed the regulation-of-autophagy (ROA)-pathway as signiﬁcant in 
bone remodeling (Zhang et al., 2010). Regulators of osteoblast differentiation 
also link to BMD; e.g. bone morphogenetic protein 2 (BMP2) (Styrkarsdottir et 
al., 2003) and osterix (SP7) in the only association study performed on pediatric 
subjects (Timpson et al., 2009). 
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Table IV. Genes linked to decreased bone mineral density based on association and 
linkage studies. *Corresponding references are marked in Table V. 
Normal font: GWAS and SNP-based candidate gene studies, Bolded: linkage study, Italic: meta-analysis. 
WB/comb: Whole body bone mineral density (BMD) or combined BMD with lumbar spine (LS) and hip BMD 
or fractures, UR: ultradistal radius, (f): only in female, (m): only in male, (p): paternal imprinting.
 	
			 			.
 	/ 0

	
/
 
	
! 	
"/
#

# 0 $ %&" '&" (
11232/)4234           
12434      )D     +
125       !    
126 	
 
;     5) #
* @ @ 
1)44            
1)42           
1)24/)52        %   
442/45           
4)11       5    
4)4532           
4)27   !)    )  5  
24732/4734      
     +
2)12/)41    !       
5)44       -)  5  
5)44       )    
5)44       +-)   5 
5)24/25           
712       5    
71734        #   
7)41/)44 )!     
   5 5 +
7)21/22          + 
641      
 - !  @  +
6)47   B      @D @- 
6)46/48           
815        %   
817          5 5 
8)41    !5!      
 
8)22       )
;   5 
911341 )         B 
9)45  
;

      !@ !@ 
:)41324/)2131      ;  %   +
:)2131/)2232           
:)25        %   
1;)45   !)        
1;)46312          5 
1111 5)          
111734    !5! !)      
11)14/12 5)        +


B
D-

11)4232           
11)47        %   
1412 5)         B 
14)12 5)    + 
)5
)   - B +
14)42/45         +  
14)45321/)           
12)14/15  ;D5     5
  @ @5
+

12)4131           
15)1231/)4531   B     % D D 
15)4232/24314        %   
17)4134   !)        
1614       5    
16)4531       !  5  
1814/)41322 
     B!;   5+ B
 +
19/)1432      )D!     +
19)41/42  ;D        @ 
19)41/45  ;
!       5  
1:)12     +)  
    
4;1432       -) (   
41)44         +  
44)11/)14       !  +  

REVIEW OF THE LITERATURE
30
Table V. References to Table IV.  A selection of genetic studies on bone mineral density. 
SNP: single nucleotide polymorphism; GWAS: genome-wide association study; GWMS: genome-wide mi-
crosatellite study.
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2.3 THE WNT PATHWAY
The wingless-type (Wnt) pathway is a complex signaling pathway which regu-
lates multiple developmental events both during embryogenesis and in adult 
tissue homeostasis. The name is derived from the ﬁrst Wnt-genes discovered: 
Wingless (Wg) in Drosophila and Int-1 in mice. Bone researchers were led to 
this pathway in 2001 when a co-receptor, the gene encoding LRP5, was identi-
ﬁed as the causative gene behind both low and high bone mass phenotypes 
(Gong et al., 2001; Boyden et al., 2002). The canonical Wnt pathway regulates 
the proliferation of osteoblasts and promotes osteogenesis (Novak and Dedhar, 
1999; Liu et al, 2009). 
Wnt signaling
Signal transduction by the Wnt family of ligands is mediated by the binding to 
the extracellular domain receptors, including Frizzled (Fzd) and LRP. Depending 
on which Fzd receptor is activated the Wnt-Fzd-complex can induce activation 
of several signalling cascades (van Amerongen et al., 2008). In the canonical 
pathway, the activation of the receptor complex induces the de-phosphor-
ylation and thereby stabilization of cytoplasmic β-catenin (Figure 2). This is 
mediated through the activation of dishevelled (Dvl) proteins and the inhibi-
tion of glycogen synthase kinase (GSK)-3. The cytoplasmic pool of β-catenin 
is increased and enables this transcription regulator to enter the nucleus and 
promote target gene transcription by binding to responsive elements of the 
lymphoid enhancer factor-1/T-cell factor (LEF-1/TCF) family (Westendorf et al., 
2004; Liu et al., 2009). 
LRP5 and LRP6 co-receptors
LRP5 and LRP6 are cell membrane receptors, bound to the membrane with a 
single trans-membrane domain. They carry extracellular binding sites for Wnt 
proteins and for dickkopf 1 (DDK1), an inhibitor of Wnt-signaling (Westendorf 
et al., 2004). The intracellular domains become phosphorylated upon forming 
of the LRP5-LRP6-Fzd receptor complex and thereby activate the cascade which 
stabilizes cytoplasmic β-catenin (Westendorf et al., 2004).
LRP5 was ﬁrst cloned and sequenced in 1998 (Hey et al., 1998) and a few years 
later mutations in this gene were revealed as the cause of both low- and high 
BMD phenotypes, resulting from loss- and gain-of-function mutations respec-
tively (Gong et al., 2001; Boyden et al., 2002; Little et al., 2002). Since then, 
approximately 60 loss-of-function mutations in LRP5 have been published. 
Homozygotes for loss-of-function mutations in LRP5 suffer from osteoporo-
sis-pseudoglioma syndrome (OPPG) exhibiting early-onset severe osteoporosis 
and blindness, and in some patients, mental retardation (Gong et al., 2001). 
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Heterozygotes have a low BMD phenotype without eye features, and variations 
in LRP5 in the general population also affect BMD (Ai et al., 2005; Hartikka et 
al., 2005; Richards et al., 2008; Saarinen et al., 2007, 2010; van Meurs et al., 
2008).  
LRP6 was also ﬁ rst sequenced in 1998 (Brown et al., 1998), but it was not until 
2007 that a mutation in LRP6 was shown to affect bone mass accrual. Only one 
mutation in a single pedigree has been published thus far (Mani et al., 2007). 
The phenotypic features include early coronary disease and osteoporosis. The 
bone phenotype has since been replicated in a mouse model (Kubota et al., 
2008). Results from association studies regarding the impact of variations in 
LRP6 on bone health are contradictory (Sims et al., 2008; van Meurs et al., 2006, 
2008).
Figure 2. Schematic presentation of the canonical Wnt pathway. Wnt ligands can 
by binding to different receptors activate several cellular pathways, which regu-
late both organogenesis in embryos and tissue homeostasis in adults. In bone tis-
sue the canonical Wnt pathway regulates osteoblast proliferation and promotes 
osteogenesis.
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3. AIMS OF THE STUDY
Osteoporosis is a complex disease, both clinically and genetically. Despite its 
high frequency in the population, and extensive research in the ﬁeld, only few 
signiﬁcant osteoporosis genes have been identiﬁed to date. In this work that 
originated from the clinical setting, children and young adults with idiopathic 
bone fragility were examined and their family members were assessed in order 
to study the extent and mode of inheritance.
The aims of the study were:
 To identify novel mutations in LRP5 in patients with OPPG
 To study the role of LRP5 and LRP6 in childhood onset primary osteoporosis
 To identify and characterize new hereditary forms of primary osteoporosis 
 To discover new genes involved in the development of primary osteoporosis
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4. MATERIAL AND METHODS
4.1 Consent and ethics committee permissions
Written informed consent was obtained from all participants and/or the par-
ents, including the controls. The studies were performed with the permission 
of the Research Ethics Committees of Helsinki University Hospital, Helsinki, 
Finland (Studies I-IV); Hospital for Sick Children, Toronto, Canada (Studies II- 
III); and University Hospital of Cologne, Germany (Study II).
4.2 Study design, subjects and clinical assessment
Study I
A Finnish three-generation family was clinically assessed based on the high 
prevalence of severe osteoporosis in the pedigree. Nineteen family members 
consented to participate in the study at the Children’s Hospital in Helsinki, 
Finland. All individuals underwent a thorough clinical examination, DXA 
(Hologic Discovery A), a radiologic assessment, and biochemical analyses on 
blood and urine samples (Table VI). Causes for secondary osteoporosis were ex-
cluded, if considered necessary based on clinical history, with appropriate labo-
ratory tests, such as markers for thyroid function, celiac disease and inﬂamma-
tory bowel disease. DNA from ﬁve unaffected parents of affected children was 
available. Four affected patients underwent bone biopsy. 
An individual was considered affected if there were signs of vertebral com-
pression fractures on spinal radiography and/or if the lumbar or femoral BMD 
Z-score was below -2.0 in premenopausal individuals under the age of 50 or the 
BMD T-score was below -2.5 in elderly or postmenopausal subjects (Lewiecki et 
al., 2008). 
As the inheritance seemed of dominant autosomal mode, genetic studies were 
undertaken. The linkage areas were identiﬁed by microsatellite screening of 
DNA samples followed by target enrichment of all exons in the linkage areas. 
DNA samples from 80 healthy Finns were available as controls.
Study II 
Study II involves patients with a clinical diagnosis of OPPG. DNA samples from 
nine OPPG-patients diagnosed at clinical centers in Germany, Norway, Canada, 
Turkey, and Iran were screened for mutations in LRP5. The four patients found 
to carry mutations affecting protein splicing were selected for this study. 
Clinical data was collected from hospital records. The impact of the mutations 
was investigated through exon trapping, cDNA sequencing and, for one muta-
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tion, by functional studies. DNA samples from 171 Finnish, 96 Caucasian (Centre 
d’Etude du Polymorphisme Humain; CEPH), and 50 Turkish healthy individuals 
served as controls. 
Study III
The study includes 27 children with primary non-OI osteoporosis, diagnosed 
and followed at The Hospital for Sick Children, Toronto, Canada, between 
January 2002 and February 2008. The inclusion criteria were I) low BMD (Z 
score < -2.0), II) a history of three or more peripheral fractures by low-impact 
trauma, and/or III) vertebral compression fractures. OI was excluded clinically in 
12 patients and by Sanger sequencing of COL1A1 and COL1A2 in 15 patients. 
Secondary osteoporosis was excluded with appropriate laboratory tests, e.g. 
tests for thyroid function, malabsorption, and sex and growth hormone lev-
els. Clinical data was collected from hospital records, vertebral morphology 
was assessed by spinal radiography, and BMD was measured with DXA (Lunar 
Prodigy, GE Lunar, Madison, WI, USA). DNA samples from the patients were 
screened for variations in LRP5, LRP6, and parathyroid hormone-like hormone 
(PTHLH). 
Sixty nuclear family members of these patients also participated in this study 
by undergoing DXA of the lumbar spine. In participating adults under the age 
of 50 years or prior to menopause, a BMD Z-score below -2.0 was considered 
“below the expected range for age” (Lewiecki et al., 2008). The standard deﬁ-
nition of osteoporosis (T-score ≤-2.5) and osteopenia (T-score between -2.5 and 
-1.0) was used for adults over the age of 50 years and for postmenopausal 
women, according to international guidelines. (WHO, 1994) Control DNA sam-
ples from healthy Caucasians were screened: 171 controls for LRP5 and 50 con-
trols for LRP6 and PTHLH.
Study IV
As a part of an ongoing project assessing clinical and genetic aspects of child-
hood onset primary osteoporosis, a child with primary osteoporosis was diag-
nosed with Calvarial doughnut lesions (CDL) at Children’s Hospital in Helsinki, 
Finland. The proband and her father were assessed for bone health by radiog-
raphy, bone densitometry (DXA, Hologic Discovery A, Hologic Inc., Waltham, 
MA, USA), and blood biochemistry (Table VI). Existing clinical, radiological, and 
biochemical data was reviewed for affected family members. Patient DNA sam-
ples were screened for mutations in the LRP5, COL1A1, and COL1A2 genes. A 
literature review was based on previously published cases of CDL in PubMed 
and ISI Web of Knowledge. 
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4.3 Bone biopsy (Studies I and IV)
Transiliac bone biopsies were obtained under local anesthesia (adults) or un-
der general anesthesia (child) from the anterior superior iliac crest with a 
bone biopsy needle of 7.5mm inner diameter (Rochester Bone Biopsy, Medical 
Innovations Incorporation, Inc., Rochester, MN) following a double-labeling 
course with oral tetracycline according to recommendations (Rauch, 2003). The 
bone specimens were intact and included both cortices separated by a trabecu-
lar compartment. After ﬁxation, bone histomorphometric analyses were con-
ducted at the Bone and Cartilage Research Unit, University of Kuopio, Kuopio, 
Finland, with a semiautomatic image analyzer (Bioquant Osteo, Bioquant 
Image Analysis Corporation, Nashville, TN). The results were compared with 
normative data (Glorieux et al., 2000; Recker et al., 1988; Rehman et al., 1994) 
and presented according to the nomenclature recommended by the American 
Society for Bone and Mineral Research. (Parﬁtt et al., 1987)
4.4 Statistics
In study II, a two-sided Student’s t-test was used to compare the signaling ac-
tivity of transfected constructs. In Study III the Χ² test was applied to compare 
DNA variant frequencies between patients and controls. A p-value <0.05 was 
considered signiﬁcant. The statistical software utilized in Study I for analysis of 
linkage LOD scores is speciﬁed below (under ”Microsatellite studies”). 
4.5 Genetic studies
The reagents, appliances and software used in genetic studies are summarized 
in Table VII.
DNA/RNA puriﬁcation and sequencing (Studies I-IV)
Genomic DNA was extracted from peripheral blood lymphocytes by standard 
methods and primers were designed to amplify exons and at least 10 bases 
of ﬂanking introns (Studies I-IV). RNA was extracted from peripheral blood 
or cultured ﬁbroblasts before reverse transcription polymerase chain reaction 
(RT-PCR) (Study II).  Genomic sequences for primer planning were obtained 
from the University of California Santa Cruz (UCSC) database and primers were 
designed with web-based primer programs Exon Primer and Primer3. Primers 
were blasted to the genome using UCSC blat. 
All exons and ﬂanking introns were analysed by Sanger sequencing from 
BCAR3 (Study I), LRP5 (Studies I-IV), LRP6 and PTHLH (Study III), and COL1A1 
and COL1A2 (Study IV). DNA was ampliﬁed by polymerase chain reaction (PCR) 
using either AmpliTaq Gold or Phusion High Fidelity DNA polymerase and 
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puriﬁed according to the manufacturer’s recommendations before BigDye-
labelling and sequencing. 
Sequence analysis (Studies I-IV)
Sequence analysis was performed with the Sequencher program. Identiﬁed se-
quence variants were compared with public genomic databases: University of 
California Santa Cruz (UCSC), National Center for Biotechnology Information 
(NCBI), 1000 genomes and National Heart, Lung and Blood Institute (NHLBI). In 
silico predictions regarding changes in protein function from sequence variants 
were performed with web-based software PolyPhen2 and SIFT, and predictions 
on changes in RNA splicing were performed with NNSPLICE0.9 and NetGene2.0. 
Control samples were screened by Sanger sequencing, except for the Turkish 
control samples in Study II, in which the investigated nucleotide change was 
excluded by digestion of PCR fragments by restriction enzyme Hphl and gel 
electrophoresis on a 1.2% agarose gel with ethidium bromide staining.
Exon trapping (Study II)
Appropriate tissue samples for RNA extraction were unavailable for two pa-
tients in Study II. The consequences of their splice site mutations were there-
fore analysed using the Exon Trapping System (Buckler et al., 1991). PCR am-
pliﬁed fragments of patient DNA were cloned into the PCR 2.1-TOPO Vector, 
subcloned into the exon trapping vector, pSPL3, and transfected by lipofection 
into COS-7 cells. After 24 hours of incubation, total RNA was isolated, cDNA 
was synthesized, and PCR ampliﬁed. The RT-PCR products were visualized on 
1.2% agarose gels by ethidium bromide staining.
Microsatellite studies (Study I)
A genome-wide microsatellite screening was performed at the Institute for 
Molecular Medicine Finland (FIMM), Helsinki, Finland, with a panel of 384 
polymorphic ﬂuorescent markers evenly spread over the 22 autosomes and 
the X-chromosome according to standard methods. Twenty-four DNA samples 
from the investigated pedigree were included in the screening (19 clinically 
assessed family members and 5 additional parents). Microsatellite analysis was 
performed with GeneMapper. LOD score analyses were performed under the 
assumption of autosomal dominant inheritance with the presumed disease-
gene frequency of 0.01, a penetrance of 90% and a phenocopy rate of 2.4%. 
Two-point linkage LOD scores were calculated with ANALYZE. For LOD scores 
detected under homogeneity, the pointwise thresholds set according to Lander 
and Kruglyak (1995) are P p .000049 (equivalent to a LOD score of 3.3) for 
signiﬁcant linkage and P p .0017 (LOD score 1.9) for suggestive linkage. Non-
parametric multipoint linkage p-scores were analyzed with Simwalk2 v.2.96 
under recessive, dominant, and additive inheritance models with the Kong and 
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Cox signiﬁcance testing procedure, where a p-value below 0.001 is considered 
as signiﬁcant evidence and a p-score below 0.01 as suggestive evidence of link-
age.  
Mistyping and haplotype analyses were performed with Simwalk 2. Haplotypes 
were visualized with the web-based program Haplopainter. A ﬁne-mapping of 
the linkage areas was executed with 45 additional markers spaced 1 cM chosen 
according to position and heterogeneity. 
Genome-wide SNP microarray (Study I)
The work was performed at FIMM. DNA from all family members was screened 
with an Illumina 610K-quad microarray chip according to the manufacturer’s 
protocol. Genotype calling and CNV analysis were performed with Illumina 
software BeadStudio.
Target enrichment and deep sequencing (Study I)
The work was performed at FIMM. Target enrichment and deep sequencing 
was performed on DNA from three affected family members. The biotinylated 
RNA oligomer (“bait”) library was planned with the net-based program eArray 
based on genomic data from the UCSC database. It was designed to, within 
the linkage areas, cover all exons with 40 bases of ﬂanking introns and all CpG 
islands, which are possible promoter areas containing multiple methylation 
sites. All baits were 120 bases long and manufactured for paired-end sequenc-
ing. The baits were planned for 3 x tiling, which means that three separate 
baits covered each base in each interval. Bait sequences were blasted to the 
genome and after removal of promiscuous probes (approx. 5%), which could 
attach to more than one location in the genome, 15279 baits remained. 
The DNA samples were fragmented with ultrasonication (Covaris S220), tagged, 
and ampliﬁed according to the Sure Select instruction manual version 1-2. DNA 
fragments were thereafter hybridized to the bait library, i.e. the selected ge-
nomic regions were captured by the biotinylated baits and separated with 
magnetic beads. The captured DNA fragments were thereafter ampliﬁed by 
PCR. Fragment size and quantity were ensured by measurements with a micro-
ﬂuidics-based platform (Bioanalyzer) between every step of the protocol.
Next-generation sequencing was performed in a single run with a Solexa se-
quencer as paired-end reading with a read length of 2x56 bases. The sequence 
alignment was executed with the Burrows-Wheeler alignment tool (Li et al., 
2009) and the variant calling with SAMtool’s pileup (Li et al., 2009). The refer-
ence assembly was the human genome version GRCh37/hg19 (http://genome.
ucsc.edu). Sequence variants common to all three subjects were compared to 
known variants in UCSC, NCBI, 1000 genomes and NHLBI databases. We ﬁl-
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tered for variants in coding, splice or regulatory regions, which occurred in 
less than 15% of the general population, as more common genomic loci with 
an impact on bone health would presumably have been identiﬁed in recent 
large-scale GWASs. The impact of a variant on protein splicing was assessed in 
silico with programs deﬁned in the “Sequence analysis” chapter. The exonic 
non-synonymous variant deemed to be deleterious to protein function by pre-
diction analysis was investigated by PCR and Sanger sequencing from all family 
members and from healthy Finnish controls. 
Functional studies (Study II)
Functional studies were performed with transient transfection of plasmid con-
structs into HEK293T-cells. The utilized constructs were: a wild type construct 
(LRP5-WT9L), a mutant construct containing the investigated mutation (LRP5-p.
E528_V529ins21), and a mutant construct (LRP5-Mut3L) containing a deletion 
of six out of nine consecutive leucine residues (c.43_60del) causing a signal-
ling defect known to hinder normal secretion of the protein. Corresponding 
constructs were also used for the secretion assay, which were truncated at 
exon 20 thereby lacking the transmembrane and cytosolic domains (LRPN-
WT9L, LRP5N-p.E528_V529ins21 and LRP5-Mut3L). All plasmids contained a myc-
epitope enabling immunodetection of LRP5 with an anti-myc antibody.
Assessment of canonical Wnt signalling activity was performed with a dual-
luciferase reporter assay. A Fireﬂy luciferase reporter gene construct (Topﬂash 
TCF reporter plasmid), which contains TCF binding sites as a target for canoni-
cal Wnt signalling activation, and Renilla luciferase vectors, for control of trans-
fection efﬁciency and normalization of luciferase activity, were co-transfected 
with the wild-type and mutant constructs. In addition, plasmids encoding 
Norrin, Frizzled-4 (Fzd4), mesoderm development candidate 2 (MesdC2), and 
receptor-associated protein (RAP) were co-transfected to optimize intracellular 
signalling and molecular transport conditions as previously described (Hsieh et 
al., 2003; Ai et al., 2005, Chung et al., 2009). The mutant LRP5-Mut3L served as 
a positive control for impaired Wnt signal transduction (Chung et al., 2009). 
Co-transfection with a control vector pcDNA3.1-LacZ was performed to as-
sure that equal amounts of DNA were transfected in each experiment. β-actin 
and calnexin antibodies served as positive controls for proper separation of 
cytosolic and membrane proteins. β-actin antibodies and Coomassie staining 
of a 60-kilodalton (kDa) protein in the conditioned medium were used as con-
trols in the secretion assay for comparable loading of cell lysate and medium 
(Western blotting).
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Table VI. Laboratory tests and radiological examinations, which were utilized 
for assessment of subjects included in the studies. The extent of examinations 
was decided individually.
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Table VII. Reagents, hardware, and software utilized in the genetic analyses. 
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5. RESULTS AND DISCUSSION 
Study I 
Clinical and genetic ﬁ ndings in a family with primary 
osteoporosis
The probands were two young brothers (Figure 3, individuals 14 and 15), who 
presented with recurrent arm fractures and multiple vertebral compression 
fractures (VCFs) in the thoracic spine. They had osteoporotic lumbar spine (LS) 
BMD Z-scores (-3.1 and -2.7) (Table VIII). There was a high prevalence of os-
teoporosis in maternal relatives and no history of osteoporosis or proneness 
to fractures in the paternal family members. The maternal grandfather and 
two of his siblings suffered from VCFs and severe kyphosis. Of the 19 family 
members assessed, eleven were regarded as affected with osteoporosis. The 
phenotype status was set as “unknown” for family members not fulﬁ lling the 
criteria set for affected individuals, as most subjects were quite young and may 
develop a disease phenotype with time. The father of the probands, who had 
never sustained a fracture or suffered from back problems, was found to have 
a low LS BMD Z-score (-2.5). As the parental origin of the probands’ phenotype 
was uncertain, they were also classiﬁ ed as “unknown”. The clinical and radio-
logic features of the family members are summarized in Table VIII. 
Figure 3. Family tree of the family with a high prevalence of early-onset oste-
oporosis. Affected individuals are marked in black, unaffected/uncertain in grey 
and unassessed in white. The disease-associated haplotypes of the two identiﬁ ed 
genomic loci with positive linkage evidence are shown in boxes under each geno-
typed individual (striped box: 1p21.3-p22.2; checkered box: 11q22.1-q22.3; empty 
box: non-carrier). Lumbar spine BMD T-/Z-scores according to Table VIII are shown 
below the boxes. Individuals with vertebral compression fractures are marked 
with an asterisk. 
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Table VIII. Clinical data for the family with a high prevalence of early-onset oste-
oporosis. Subjects are numbered according to that of Figure 3. BMD values are 
presented in T-scores for subjects over the age of 50 years and in postmenopau-
sal women (values bolded) and in Z-scores for the others. The most severe verte-
bral changes found in spinal X-rays are presented according to Genant grading in 
adults (capitals) and according to Mäkitie in children.  Probands are marked with 
italic font.
†Subject 10 had osteoporotic BMD values prior to our study and had received bisphosphonate treatment 
for several years. 
BMD T- (bolded) or Z-score 
Subject Sex Age (y) Peripheral fractures (n) 
Age at first 
fracture (y) 
lumbar hip  whole body 
vertebral 
changes 
Loss of adult 
height (cm) 
Affected        
1 M 65 4 33 -4.0 -1.4 -2.3 3C 11 
2 M 62 3 7 -5.0 -3.1 -3.8 3C 12 
3 F 59 8 5 -3.6 -1.5 -3.0 3C 4 
5 F 33 0   -2.2 -1.5 -2.0 0 0 
6 F 40 0   -2.7 -1.7  n/a 0 0 
10 F 53 1 38 -1.9† -2.1 -2.1 0 0 
12 M 11 0   0.2 -0.2 0.4 2a/3a 0 
16 M 35 1 21 -1.9 -1.2 -2.5 3C 2.5 
17 M 33 10 7 -2.7 -0.7 -2.2 3C 1.5 
Status set as unknown in genetic analysis    
4 M 41 0   -1.6 -0.3 -0.4 0 0 
8 M 31 2 18 -1.3 -1.1 -1.7 0 0 
13 F 13 0   -1.7 0.4 -0.5 0 0 
14 M 12 4 8 -2.7 -2.0 -2.3 2a 0 
15 M 9 2 8 -3.1 -1.8 -2.2 3b 0 
7 M 53 0   -1.0 -0.8 -1.6 0 0 
9 F 41 1 12 -0.1 -0.3 0.7 0 0 
11 F 34 0   0.5 0.4 0.5 0 0 
18 M 30 2 16 -0.4 -0.3 -0.1 0 0 
19 F 19 0   0.4 1.2 1.0 0 0 
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Clinical and radiographic ﬁ ndings 
The affected subjects had no features of OI nor any distinct facial or body fea-
tures.  They presented normal joint laxity, their hearing and teeth were nor-
mal, and they had white sclerae. In juvenile subjects, bone age was appropriate 
for chronological age conﬁ rming normal skeletal maturation. All individuals 
were of normal height. There was a high frequency of peripheral fractures 
from low-impact trauma among affected individuals. The radiographic fea-
tures included poor mineralization of the long bone metaphyses, but normal 
cortical width and shape in the diaphyses. The ﬁ rst and most severely affected 
skeletal region was the thoracic spine. We found anterior vertebral wedging 
in a young subject. The wedging had progressed into complete VCFs in older 
individuals, and patients in their 60s had severe VCFs in virtually all vertebrae, 
which caused signiﬁ cant kyphosis and an adult height loss of up to 12 cm. 
The severity of symptoms and ﬁ ndings varied between the affected subjects; 
the ﬁ ndings tended to be more severe in males. The VCFs seemed to develop 
gradually with no pain or other symptoms, apart from subject 3 who had expe-
rienced several painful VCFs. Spinal X-rays of the affected subjects at different 
ages are presented in Figure 4. 
Figure 4. A. A 12-yearold male (12) had wedging of thoracic vertebrae grade 2b to 
3b. B. A 33-yearold male ( 17) exhibited multiple VCFs grade 3C. C. This 62-yearold 
male ( 2) had severe VCFs (grade 3C) in virtually all visible vertebrae.
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Biochemical ﬁndings
All markers of calcium and phosphate homeostasis were normal, however one 
affected subject demonstrated mild hypovitaminosis D. No patients had hyper-
calciuria or hyperparathyroidism. All measured markers of bone formation and 
degradation were within normal age-speciﬁc ranges. Exclusion of secondary 
causes of osteoporosis was performed by clinical examination and appropriate 
laboratory tests. 
Histomorphometric ﬁndings 
In the probands (14, 15), the histology and histomorphometry based on transil-
iac bone biopsies showed low bone volume, thin bone trabecuale and a normal 
or predominantly resorptive bone turnover (Figure 5). The lamellar structure of 
the bone was normal based on polarizing microscopy, but mineralization rates 
were decreased. One young male (12) had normal bone volume, but clearly de-
creased trabecular thickness (-3 SD) compensated for by an increased number 
of trabeculae. His bone turnover and mineralization rate were normal. One 
adult male (17) had severe osteoporosis. His bone trabeculae were thin and 
scarce, and bone turnover was dominated by resorption. The mineralization 
rate was normal. (Table IX) 
Table IX. Bone histomorphometry ﬁndings in four patients with hereditary oste-
oporosis. The numbers (#) in parentheses correspond to the numbering in Figure 
3 and Table VIII. Values low for sex and age are noted in bold, and high values are 
underlined.
BV/TV, bone volume/tissue volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; O.Th, osteoid thick-
ness; W.Th, wall thickness; OS/BS osteoid surface/bone surface ; OV/BV, osteoid volume/bone volume; Ob.S/BS, 
osteoblast surface/bone surface; ES/BS, eroded surface/bone surface; Oc.S/BS, osteoclast surface/bone surface; 
MAR, mineral apposition rate. N/A: not available. Age- and sex-speciﬁc reference values are given for each 
parameter in parentheses (mean ± SD). (for children: Glorieux et al., 2000; for the adult: Rehman et al.1994) 
Male, 11 years Male, 33 years Male, 9 years Male, 12 years 
Parameter 
(#12) (#17) (#15) (#14) 
BV/TV (%) 23.6 (24.4 ± 4.3) 11.1 (22.0 ± 3.9) 13.8 (24.4 ± 4.2) 9.2 (24.4 ± 4.3) 
Tb.N (/mm) 3.1 (1.66 ± 0.22) 1.3 (1.7 ± 0.4) 1.8 (1.78 ± 0.17) 1.3 (1.66 ± 0.22) 
Tb.Th (.m) 77.1 (148 ± 23) 88.4 (138 ± 24) 78.0 (129 ± 17) 69.0 (148 ± 23) 
O.Th (μm) 6.4 (6.7 ± 1.7) 6.4 (9.7 ± 4.6)  6.3 (5.9 ± 1.1) 9.1 (6.7 ± 1.7) 
OS/BS (%) 13.5 (22.1 ± 7.8) 5.6 (14.0 ± 4.6) 13.8 (29.1 ± 12.9) 13.7 (22.1 ± 7.8) 
OV/BV (%) 1.7 (2.1 ± 1.0) 0.8 (3.5 ± 1.9) 2.2 (2.6 ± 1.0) 1.8 (2.1 ± 1.0) 
Ob.S/BS (%) 3.5 (6.7 ± 4.5) 1.9 (6.0 ± 1.1) 4.0 (8.2 ± 4.4) 6.5 (6.7 ± 4.5) 
ES/BS (%) 4.6 (14.9 ± 5.6) 5.5 (4.5 ± 1.9) 12.8 (17.0 ± 6.0) 3.9 (14.9 ± 5.6) 
Oc.S/BS (%) 0.8 (0.9 ± 0.4) 3.4 (0.6 ± 0.4) 4.2 (1.3 ± 0.6) 0.5 (0.9 ± 0.4) 
MAR (μm/day) N/A 0.5 (0.6 ± 0.3) 0.5 (0.9 ± 0.1) 0.6 (0.9 ± 0.1) 

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Figure 5. Histomorphometry of a bone sample from a 12-yearold boy (14). A modi-
ﬁed Masson-Goldner trichrome stain was used (bone, green; osteoid, red). Bone 
trabeculae are thin and scarce, but the amount of osteoid is normal. 
Genetic results
Multipoint non-parametric linkage (NPL) analysis using an additive model re-
vealed p-values of suggestive linkage in 1p22.1 at adjacent markers D1S2868 
(p=0.0040) and D1S206 (p=0.0054). (Kong and Cox, 1997) After ﬁne mapping, 
recombinations at D1S435 and D1S2819 in individuals 10 and 12 restricted the 
area to a 4.9 Mb region at 1p21.3-p22.2. In chromosome 11, marker D11S4175 
had a NPL p-value of 0.0328. Based on haplotype analysis, this area was in-
cluded in the ﬁne mapping. Thereafter the lowest NPL p-value was 0.007 at 
D11S898 in 11q22.1, and the shared region stretched from marker D11S4210 to 
D11S2000 (11q22.1-q22.3). Two-point LOD-scores were assessed and haplotype 
analysis of all chromosomes was performed, but since no family members were 
classiﬁed as healthy in the analysis, the statistical strength of the two-point 
LOD-score analysis suffered and the best correlation between phenotypes and 
haplotypes was found with the multipoint NPL analysis. No shared haplotype 
was identiﬁed in the X-chromosome (data not shown). Linkage analysis results 
are visualized in Figure 6. Neither of the presented regions of interest could 
alone explain the phenotype of the family. Genomic deletions segregating ac-
cording to the haplotype analysis, or shared by the probands and their father, 
were excluded by a microarray CNV analysis. As the inheritance based on the 

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linkage analysis was suggestive of multigenic origin, all exons in the identiﬁ ed 
regions were sequenced in order to look for putative disease-causing muta-
tions.  
Target enrichment and next-generation sequencing analysis was performed on 
three affected individuals (1, 2 and 17); they shared 66 heterozygous sequence 
variants within the targeted regions. All variants could be found in public data-
bases. Since the disease-causing changes in this pedigree are presumably clini-
cally signiﬁ cant,  SNPs which occur in less than 15% of the general population 
according to data from the 1000 genomes database were ﬁ ltered. It was postu-
lated that recent large-scale GWASs would have identiﬁ ed more common loci 
with effect on variations in BMD and proneness to fracture (Rivadeneira et al., 
2009; Estrada et al., 2012). Out of the remaining 18 variants, only ﬁ ve resided 
in coding regions, near splice sites, or in regulatory regions. One was a synony-
mous SNP and one an intronic variation residing seven bases downstream of a 
splice site. Neither variation was predicted in silico to alter protein splicing. The 
three remaining SNPs were missense variants, which resided in breast cancer 
anti-estrogen resistance 3 (BCAR3) in chromosome 1, and in matrix metallopro-
teinase 10 (MMP10) and dynein, cytoplasmic 2, heavy 1 (DYNC2H1) in chromo-
some 11. Only the change in BCAR3 was predicted to be deleterious to protein 
function. Next generation sequencing artifacts and correct allele distribution 
according to haplotype analysis were conﬁ rmed by Sanger sequencing of this 
region in BCAR3 from DNA samples of all family members and 60 controls. 
This variant could be found at a low frequency (3.1%; 5/160 alleles) in healthy 
Finnish controls. (Table X)
Figure 6. Plot of two-point LOD-scores (blue) and multipoint non-parametric link-
age p-scores presented as –log10(p) values (pink; Kong&Cox statistics, additive 
model) for chromosomes 1-22.
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Table X. The results from the genetic analysis performed on a pedigree with a 
high prevalence of osteoporosis. The affected family members largely shared two 
genomic regions based on microsatellite linkage and haplotype analysis. The tar-
geted next-generation sequencing of these linkage areas revealed ﬁve shared het-
erozygous variations, three of which were non-synonymous, after ﬁltering of re-
sults. LOD: maximum two-point LOD-score; NPL: lowest multipoint non-parametric 
linkage p-value; MAF: minor allele frequency in the general population based on 
the 1000 genomes database.
To conclude: The investigated family was identiﬁed based on two severely 
affected brothers, who had sustained multiple peripheral and vertebral frac-
tures. Upon assessment of 19 family members the inheritance seemed auto-
somal dominant. Affected family members suffered from mild VCFs in child-
hood and low BMD in adulthood. With increasing age, the affected individuals 
sustained severe VCFs of thoracic, and later lumbar, vertebrae. No other phe-
notypic features could be identiﬁed and bone turnover markers were normal. 
OI was excluded clinically and based on linkage analysis, and no mutations 
could be found in LRP5. Two regions with NPL p-score indicative of suggestive 
linkage were identiﬁed in 1p21.3-p22.2 and 11q22.1-22.3, none of which alone 
could explain the clinical phenotype. One of the probands did not carry either 
of the regions shared by affected maternal relatives. His father also had low 
BMD-values, but the phenotype of the boy resembled more that of maternal 
family members. Next-generation sequencing of all exons and ﬂanking introns 
in the identiﬁed regions revealed three non-synonymous variations, one of 
which was predicted to damage protein function. This variation occurs at a low 
frequency in the general population. 
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In the most signiﬁcant linkage area, in chromosome 1, the only missense vari-
ation common to most affected patients resided in BCAR3. BCAR3 is a gene 
involved in anti-estrogen resistance in breast cancer treatments (van Agthoven 
et al., 1998). The signiﬁcance of this gene with regard to bone health is un-
clear. In chromosome 11, both discovered variants were predicted to be be-
nign. The variant in MMP10 has, however, been linked to the risk for ligament 
rupture in the knee, and the gene has been implicated in osteoarthrosis stud-
ies, indicating a role in cartilage and ligament maintenance (Kevorkian et al., 
2004; Posthumus et al., 2011). DYNC2H1 is involved in protein transportation in 
the primary cilium, which is also the mechanosensory organ of the osteocyte. 
Biallelic mutations in DYNC2H1 cause polydactyly-short-rib syndrome, but the 
variant identiﬁed here has not been linked to this disease; the phenotype in 
heterozygotes is not known (Hoey et al., 2011; Merrill et al, 2009; Dagoneau et 
al., 2009). Future functional studies are needed to clarify the signiﬁcance of the 
discovered variations with regards to bone homeostasis.
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Study II 
LRP5 mutations affecting splicing
OPPG is a rare autosomal recessive syndrome caused by loss-of-function muta-
tions in LRP5. 
The phenotype of our patients is typical for OPPG: loss of vision in infancy and 
severe symptomatic osteoporosis presenting in childhood as VCFs, long bone 
low-impact fractures, and bowing. About 25% of reported cases show mental 
retardation (Ai et al., 2005).  
All of our patients are congenitally blind with diagnoses of exudative retinopa-
thy (Patient 1), retrolental ﬁbroplasia (Patients 2, 3A, and 3B) and bilateral cat-
aract, right microphthalmia, left retinal calciﬁcations, and absent visual evoked 
potentials (Patient 4). Patient 2 has severe mental retardation and epilepsy; the 
other patients have normal psychomotor development. Patient 1 has unrelated 
parents of Eastern European origin and Patients 2-4 consanguineous parents 
from the Middle East. Their bone phenotypes are described separately below.
Clinical ﬁndings
Patient 1 is a 13 year-old girl, who sustained a lower leg fracture at 2 and a 
forearm fracture at 5 years of age. The clinical diagnosis of OPPG was set at age 
5 when she was diagnosed with multiple VCFs and severe osteoporosis (LS BMD 
Z-score -3.8). From 6 to 10 years of age she received bisphosphonate treatment 
with dinatriumpamidronate 1.0 mg/kg/day for three consecutive days every 
four months. Her LS BMD Z-score increased to -1.6 and spinal compression frac-
tures improved with treatment. According to her parents, the medication also 
improved her strength and physical well-being. Her BMD and clinical status 
have remained stable after discontinuation of bisphosphonate treatment. Both 
parents are osteopenic (LS BMD Z-score -2.1) and their vision and eye examina-
tions are normal. The mother has sustained one forearm fracture.
Patient 2 is a 13-year-old mentally retarded boy with complex partial seizures 
well-controlled with anticonvulsant medication. His brain MRI is normal. After 
sustaining four femoral fractures between 3 and 7 years of age he has not been 
able to walk independently. He receives bisphosphonate therapy (alendronate 
70 mg orally once a week) since three years. His LS BMD Z-score has improved 
from -2.0 to -1.4 and the total body BMD Z-score from -3.3 to -2.4. He has not 
sustained fractures while on medication and is now able to walk with support. 
Both parents have osteopenia, use eyeglasses for reading but report no other 
visual problems. The father has adult-onset diabetes treated with insulin. 
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Patients 3A and 3B are young adult brothers of normal intelligence. They have 
been wheelchair-dependent since adolescence due to skeletal deformities 
from multiple low-impact fractures (radius, humerus, and/or the hip, from age 
11 and 7 years, respectively). They have severe osteoporosis; the current LS 
BMD Z-score of patient 3A is -5.3. The father (age 55) has osteoporosis (LS BMD 
Z-score -3.1), and the mother (age 55) is osteopenic. 
Patient 4 is a 17-year-old male who suffers from bilateral tibial bowing and 
VCFs since the age of 6. He has no history of peripheral fractures. He can stand 
unsupported but needs support when walking, mainly due to visual problems. 
A recent radiographic skeletal survey revealed generalized osteoporosis, scol-
iosis, dorsal kyphosis, severe ﬂattening and biconcave appearance of the verte-
brae, and bowing and deformation of the long bones.
Genetic ﬁndings and functional studies
Sanger sequencing of LRP5 revealed that Patient 1 is a compound heterozygote 
for a missense mutation c.1067C>T (S356L) in exon 6 and a splice site mutation 
c.4112-2A>G (intron 19). The patient’s mother is heterozygous for the c.1067C>T, 
and the father for the c.4112-2A>G mutation. The mutant protein encoded by 
the allele harboring the S356L mutation is known to trafﬁc normally but is un-
able to transduce Wnt1 and Wnt10b signals (Ai et al., 2005). Since no tissue 
samples or RNA from this patient were available to conﬁrm that the c.4112-
2A>G splice site mutation impaired splicing, a heterologous splicing assay was 
undertaken (Figure 7). Patient DNA fragments were inserted into the cloning 
site of a pSPL3 plasmid. This plasmid contains a multiple cloning site within an 
intron, which is ﬂanked by splice donor and acceptor sites of two open reading 
frames (Buckler et al., 1991). In the absence of an inserted fragment, transfected 
cells remove the endogenous intron to generate a vector/vector product of 263 
base pairs (bp) (Figure 7A, lane 6; Figure 7B, α splicing product). In the presence 
of an inserted wild-type fragment a spliced vector/genomic product containing 
the inserted fragment is produced in addition to the vector/vector product of 
263 bp (Figure 7A, lane 2; Figure 7B, β splicing product). Mutant constructs did 
not produce any detectable vector/genomic product from the mutant insert ob-
tained from Patient 1 (Figure 7A, lane 3), which indicates that the substitution 
of the splice acceptor site (AG to GG) of intron 19 promotes splicing out of exon 
20 and adjoining introns without activation of cryptic splice sites. The in-frame 
splicing out of exon 20 in Patient 1 does not cause a stop codon, but completely 
removes the transmembrane domain of the protein. 
Patient 2 carries a homozygous splice site mutation c.1015+1G>T (intron 5), and 
both parents are conﬁrmed to be heterozygous for the mutation. The heter-
ologous splicing assay of this mutant construct, containing a substitution in the 
donor splice site from GT to TT, showed that exon 5 with its adjoining introns is 
consistently spliced out. This is illustrated by the 263 bp vector-vector product in 
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Figure 7A (lane 5), as opposed to the presence of a 395 bp vector/genomic prod-
uct produced by the vectors containing the wild-type exon 5 fragment (Figure 
7A, lane 4). The in-frame splicing out of exon 5 in Patient 2 generates a prema-
ture stop codon at amino acid position 295, created by the junction of exons 4 
and 6. The patient’s mental retardation and severe phenotype could be thought 
to derive from the truncation of both alleles at the start of exon 5. The major-
ity of mutations in LRP5 which have been linked to mental retardation induce 
truncation of the protein (Ai et al., 2005). On the other hand, normal cogni-
tive development has been reported in other homozygous OPPG patients with 
severe protein truncations, and mental retardation has been reported in both 
homozygous and compound heterozygous OPPG patients (Ai et al., 2005). This 
indicates that additional factors inﬂuence mental development and no speciﬁc 
domain with regards to genotype-phenotype correlation and mental retarda-
tion can be found (Ai et al., 2005).
Patients 3A and 3B are homozygous for a splice site mutation c.1584+4A>T 
downstream of exon 7 in LRP5. The mutation was present in the heterozygous 
state in the patients’ parents and was absent in 50 control samples. Splice site 
mutations at position +4 are rare, accounting for less than 2% of all donor-
site mutations (Krawczak et al., 2007). According to in silico splice site analy-
ses the wild-type splice donor site has a splice prediction score of 0.99 (the 
maximum value being 1.00), whereas the splice score of the mutated sequence 
c.1584+4A>T is only 0.44. RT-PCR revealed that the mutation inactivates the 
original splice site. This induces the activation of a cryptic splice site 63 basepa-
irs downstream of the original splice site (Figure 8A) and an in-frame insertion 
of 21 amino acids (p.E528_V529ins21) from intron 7 after the amino acids en-
coded by exon 7. The wild-type sequence is correctly spliced in a control sample 
(Figure 8B). 
To assess the activity of the canonical Wnt-pathway with regards to the splice 
site mutation, a dual-luciferase reporter assay (Topﬂash) was undertaken. The 
Fireﬂy luciferase reportergen construct, which reﬂects activation of canonical 
Wnt signalling, was co-transfected with the wild-type (LRP5-WT9L) and mutant 
(LRP5-p.E528_V529ins21) constructs, and with plasmids which optimize signal-
ling and molecular transport conditions. Renilla luciferase vectors were trans-
fected for control of transfection efﬁciency and normalization of luciferase ac-
tivity. The mutant construct LRP5-Mut3L served as a positive control for impaired 
Wnt signal transduction. Activities of the mutant LRP5-p.E528_V529ins21 were 
signiﬁcantly lower than those of LRP5-WT9L (p values <0.001 in a two-sided 
Student’s t-test calculation) indicating a disturbance in the activation of the 
Wnt signaling cascade. The c.1584+4A>T splice site mutation of the LRP5 recep-
tor severely impaired signal transduction (Figure 9A). 
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Figure 7. Splicing assay with the Exon Trapping system.  
(A) cDNA from COS-7 cells containing wild-type and mutant constructs (exon 20 
from Patient 1 and exon 5 from Patient 2) was PCR ampliﬁ ed and visualized on an 
ethidium bromide gel. Lane 1 contains a DNA sizing marker. Splicing products from 
constructs are visualized on lanes 2 to 6: Lane 2: wild-type exon 20; Lane 3: mutant 
exon 20; Lane 4: wild-type exon 5; Lane 5: mutant exon 5; Lane 6: empty pSPL3-
plasmid. A vector/vector splice product of 263 bp is produced in the absence of an 
inserted fragment (A: Lane 6, B: α splice product). Splicing of the vector gives rise 
to two products in the presence of an inserted wild-type fragment: an abundance 
of correctly spliced vector/genomic product containing the inserted exon (237 or 
132 bp; A: Lanes 2 and 4, B: β) and a smaller amount of the “empty” vector/vector 
product of 263 bp.  No detectable vector/genomic product could be retrieved from 
mutant constructs containing the inserts obtained from Patients 1 and 2 (Lanes 3 
and 5) indicating complete splicing out of exons 20 or 5.
 
(B) A schematic description of the exon trapping vector, pSPL3, and genomic DNA 
constructs: intronic vector DNA (white), exonic vector DNA (blue), intronic genomic 
DNA (light grey) and exonic genomic DNA (dark grey) are indicated. The two possi-
ble splicing pathways are shown with their respective spliced products: α (vector/
vector) and β (vector/genome). 
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Figure 8. Identiﬁ cation of the c.1584+4A>T disease-causing splice site mutation in LRP5.
(A) Genomic DNA amplicons of the LRP5 exon 7 splice donor site assessed by Sanger 
sequencing in a control individual (wild-type sequence) and Patient 3A (mutated 
sequence). Based on in silico analyses of the sequence, the predicted splice score 
decreases from 0.99 in the wild-type splice donor site to 0.44 in the mutated se-
quence inducing the activation of a cryptic splice donor site downstream. 
(B) Electropherograms of LRP5 cDNA amplicons from Patient 3A (upper panel) 
and a control individual (lower panel) revealing a mutated splice donor site after 
exon 7. The patient cDNA sample contains 63 additional nucleotides of intron 7 
inserted into the mRNA molecule of exon 7 in the patient sample, whereas the 
control sample is correctly spliced.
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To ensure the validity of the transfections and protein stability, a Western blot 
of cell lysates from transiently transfected HEK293T cells used in the dual-luci-
ferase reporter assay was undertaken. Immunodetection of the plasmids with 
an anti-myc antibody conﬁrmed stable expression of both wild-type and mu-
tated LRP5 receptors (Figure 9B). β-actin antibodies served as loading controls 
for equal amounts of cell lysates. 
To determine whether the mutated LRP5 receptor was correctly inserted into 
the membrane of the endoplasmatic reticulum (ER), the membrane fraction 
from the cytosolic fraction of transiently transfected cells was separated. Both 
wild-type and mutated LRP5 were almost exclusively detectable in the mem-
brane fraction (Figure 9C), which indicated correct insertion of the mutated 
protein into the ER membrane. To further track the molecular basis of the LRP5 
loss-of-function, a secretion assay was performed with truncated constructs, 
which lack the transmembrane and cytosolic domains. The wild-type protein 
construct was secreted into the medium when normally trafﬁcked within the 
cell, as conﬁrmed by Western blotting, but the mutant was almost completely 
absent from the medium (Figure 9D) as was the LRP5N-Mut3L-construct serving 
as negative control. Our experimental data thereby indicates that the 21 amino 
acid insertion causes a disruption of the intracellular protein trafﬁcking of the 
receptor. This may be the consequence of a conformational change in the re-
ceptor interfering with molecular interactions required for proper transport 
to the cytoplasmic membrane and would explain the severely reduced signal 
transduction observed for the mutant LRP5 receptor in the luciferase reporter 
assay.
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Figure 9. Functional studies with mutant LRP5 protein. 
(A) Assessment of the canonical Wnt signalling activity with a dual-luciferase re-
porter assay.  Relative luciferase activities (average and standard deviation) of 
empty vector (pcDNA3.1), wild-type LRP5 (LRP5-WT9L), and the mutant LRP5-p.
E528_V529ins21 are depicted in the graph. The mutant construct LRP5-Mut3L served 
as a positive control for impaired Wnt signal transduction. 
(B) Normal expression of LRP5-WT9L and of the two mutated LRP5 receptors were 
conﬁ rmed by Western blot of cell lysates from transiently transfected HEK293T 
cells. All plasmids contain a myc-epitope enabling immunodetection of LRP5 with 
an anti-myc antibody. 
(C) Cell fractioning assay of HEK293T cells transiently transfected with LRP5-WT9L 
or LRP5-p.E528_V529ins21. Calnexin and β-actin antibodies served as positive con-
trols for proper separation of cytosolic and membrane proteins. Both LRP5-WT9L 
and p.E528_V529ins21 are almost exclusively detectable in the membrane frac-
tion.
(D) Secretion assay by Western blotting of conditioned medium (CM) and cell lysate 
(LY) from HEK293T cells transiently transfected with plasmid constructs containing 
the truncated proteins LRP5N-WT9L, LRP5N-p.E528_V529ins21 and LRP5N-Mut3L. 
Immunodetection of membrane-marker beta-actin in cell lysates or by Coomassie 
staining of a 60-kDa protein in the conditioned medium were used as controls for 
comparable loading. Only LRP5N-WT9L is strongly detected in conditioned medi-
um, while the mutated constructs LRP5N-p.E528_V529ins21 and LRP5N-Mut3L were 
found only in cell lysate indicating disturbed protein secretion.  
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Patient 4 was homozygous for common polymorphisms in LRP5, but no pu-
tative disease-causing mutations could be identiﬁ ed upon Sanger sequencing 
of LRP5. The PCR ampliﬁ cation of exon 4 was repeatedly unsuccessful in this 
patient despite several different primer combinations which produced normal 
ampliﬁ cation products in control samples. cDNA sequencing revealed the loss 
of exons 4 and 5 in the patient sample (Figure 10A). As exons 3, 5 and parts of 
intron 3 could be sequenced from the genomic DNA of Patient 4 (Figure 10B), 
the most probable explanation is a homozygous deletion involving exon 4 and 
part of the adjacent introns. The ampliﬁ cation of a PCR-fragment spanning the 
breakpoints was repeatedly unsuccessful. 
Figure 10. (A) Electropherograms of LRP5 cDNA amplicons from Patient 4 and a 
control revealing the loss of exons 4 and 5. (B) PCR-ampliﬁ ed genomic DNA frag-
ments from Patient 4 and controls visualized on a 2% ethidium bromide gel. All 
studied amplicons; exons 3, 4 and 5, areas of intron 3 (a: 2735-3671 nucleotides 
and b: 4198-4503 nucleotides downstream of exon 3) and intron 4 (607-1213 nu-
cleotides downstream of exon 4) could be detected in two control samples (C) and 
are clean in water samples (0) serving as negative controls. PCR ampliﬁ cation was 
repeatedly unsuccessful from patient (P) DNA in the areas of intron 3b, exon 4 and 
intron 4, suggesting a homozygous deletion of exon 4 and adjacent intronic parts. 
Exon 5 and at minimum of 10 adjoining intronic nucleotides could be sequenced 
from both patient and control samples.
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To conclude: The presented cases are patients with typical phenotypic features 
of OPPG. For this study, patients with mutations affecting the splicing of LRP5 
were selected. Prior to this study, only four splice site mutations in LRP5 had 
been published (Ai et al., 2005; Narumi et al., 2010) and this was the ﬁ rst report 
evaluating the effect of human LRP5 splice aberrations on the function of the 
respective LRP5 protein.
Two of the mutations in these patients affect immediate and highly conserved 
splice sites (+/- 2 bases from exons). Both substitutions, AG to GG of the splice ac-
ceptor site and GT to TT of the donor site, are common causes of exon skipping 
(Baralle et al., 2008). Due to the lack of tissue samples and RNA from Patients 1 
and 2, a heterologous splicing assay was used to conﬁ rm exon skipping and ex-
clude activation of cryptic splice sites. For Patient 1, the loss of exon 20 removes 
the entire transmembranic domain of the encoded protein and hinders its func-
tion as a cell-surface signalling receptor. For Patient 2, the splicing out of exon 5 
induces a premature stop codon before the ﬁ rst YWTD propeller in LRP5. 
The splice site mutation c.1584+4A>T in Patient 3 resulted in the insertion of 
21 amino acids into the second beta-propeller of the extracellular part of LRP5. 
(Figure 11) The same insertion has recently been found in a Japanese patient 
who carries a different mutation affecting the same splice site: c.1584+1G>A 
(Narumi et al., 2010). Both these mutations inactivate the donor splice site, 
which activates the same cryptic splice site downstream. The insertion disturbs 
the intracellular transport of the protein thereby hindering its transit to the cell 
membrane and its function as a receptor.
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Figure 11. Schematic presentation of LRP5 and the areas affected by the mutations 
presented in this study. 1. The splicing out of exon 20 in Patient 1 removes the 
transmembrane domain of the protein. 2. The in-frame splicing out of exon 5 in 
Patient 2 induces a stop codon at the ﬁ rst EGF domain. 3. In Patient 3, the insertion 
of 21 amino acids after exon 7 affects the second β-propeller between two YTWD 
domains. 4. The loss of exons 4 and 5 in Patient 4 causes the loss of the last YWTD 
domain in the ﬁ rst β-propeller and the entire ﬁ rst EGF domain.
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The fourth mutation was a deletion of exon 4 with parts of the adjoining introns 
causing the loss of exons 4 and 5 in the cDNA. The loss of exon 5 may be due to 
loss of splice enhancer elements in intron 4. This large deletion, which removes 
the ﬁ rst EGF domain and an adjacent YWTD domain in the extracellular domain 
of this receptor protein, is likely to signiﬁ cantly impair the protein function and 
the ﬁ nding conﬁ rms the involvement of LRP5 in the patient’s disorder.
The beneﬁ cial results of treatment with bisphosphonates in Patient 1 are in con-
cordance with previous reports (Bayram et al., 2006; Barros et al, 2008; Streeten 
et al., 2008).  Low BMD was diagnosed in all six heterozygous carriers who under-
went DXA; one had osteoporosis and ﬁ ve osteopenia. This supports previously 
published data indicating a dominant negative effect on BMD of heterozygous 
LRP5 mutations (Saarinen et al., 2010). One parent has adult-onset diabetes 
mellitus. Diabetes does not seem to be a common complication in OPPG, but 
studies on a large OPPG-family and a mouse model show over-representation of 
hyperglycemia through beta-cell dysfunction and of dyslipidemia (Fujino et al., 
2003; Saarinen et al., 2010).  Larger studies on heterozygous mutation carriers 
are necessary to explore the possible link between LRP5 mutations and meta-
bolic diseases.
Study III 
Clinical and genetic ﬁ ndings in children with primary 
osteoporosis
The principal aim of this study was to better characterize primary non-OI oste-
oporosis in children; an increasingly recognized but poorly deﬁ ned condition. 
This condition, also called idiopathic juvenile osteoporosis (IJO), has previously 
been described as a syndrome presenting around puberty with multiple frac-
tures, vertebral compression fractures (VCF), and progressive kyphosis, bone 
pain, and anthalgic gait (Dent and Friedman, 1965; Smith, 1995) leading to a 
spontaneous recovery before adulthood. The age of onset is, however, more 
variable than previously thought. Many patients remain symptomatic in adult-
hood, some with severe sequelae from their osteoporosis (Smith, 1995).
Clinical ﬁ ndings
The 27 children included in this study presented with symptoms of their os-
teoporosis at age 3.3 to 15.6 years (median age 10.1 years), which is in con-
cordance with the wide age variation at presentation from nine months to 13 
years age published by Smith (1995). Age at ﬁ rst fracture ranged from 1.2 to 
16 years. Fifteen patients had recurrent low-impact peripheral fractures (n>3), 
most commonly in the radius, tibia/ﬁ bula, or clavicle. The median number of 
peripheral fractures was 3.0 (range 0-10). Twelve patients had VCFs at ﬁ rst as-
sessment and six patients with a normal spine at the ﬁ rst assessment had sus-
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tained VCF at follow-up. Sixteen patients had a BMD Z-score below -2.0 (Table 
XI). No gender predominance was observed; however, females tended to be 
more severely affected. According to guidelines from the International Society 
for Clinical Densitometry, the diagnosis of osteoporosis requires the presence 
of both a clinically signiﬁcant fracture history and low BMC or BMD (Baim et 
al., 2008). Ten of our patients demonstrated a BMD Z-score greater than -2.0. 
However, their clinical picture was that of recurrent fractures and VCF. 
As in previous studies, none of the biochemical markers of bone metabolism 
were diagnostic or indicative of disease severity. IJO has earlier been coupled 
to hypercalciuria, but only seven of our patients demonstrated mild hypercal-
ciuria at study assessment (Urine calcium / creatinine ratio ≥ 0.7 mmol/mmol). 
No abnormalities in Ca, PTH, or ALP could be found in our cohort.  Two patients 
were vitamin D deﬁcient (<37.5 nmol/L) and two patients had IGF-1 levels be-
low the normal range for age.  
We recruited 60 family members from all 24 families of the index patients. 
BMD measurement was performed on 18 fathers (median age 41.6 years, range 
31.3-57.6 years), 22 mothers (median age 40.7 years, range 32.1-53.9 years), 11 
brothers (median age 13.4 years, range 7.1-17.5 years), and nine sisters (median 
age 9.3 years, range 7.4-16.8 years). 
In contrast to earlier studies, a strong genetic component seemed to be evident 
in our cohort. Osteopenia and osteoporosis were common in both fathers and 
mothers (Table XI). Eight mothers and seven fathers had BMD values in the os-
teopenic range, and two fathers and one mother had a BMD T-score below -2.5, 
which is indicative for osteoporosis (Khan et al., 2004; Kaufman et al., 2008). 
In further support of heredity, there were three families with affected sibling 
pairs and at least one parent with low BMD. In the ﬁrst family, the younger sis-
ter (1A) presented at age 11 with recurrent peripheral fractures and VCF, while 
her symptomless older brother (1B) was found to have a thoracic VCF and low 
BMD (Z-score -2.1) upon study assessment. The father had a history of recurrent 
fractures and both parents were osteopenic (BMD T-scores -2.2 and -2.0). In 
the second sibling pair, the older sister (10A) presented with an anthalgic gait. 
She had VCFs, a BMD Z-score of -1.5 but no history of peripheral fractures. Her 
younger brother (10B) presented with the same symptoms and several VCFs. 
The father had osteoporosis (BMD T-score -2.7). In the third family the brother 
(15B) presented at age 10 years with VCFs after a fall.  His BMD Z-score was 
-2.0. At ﬁrst assessment his sister’s (15A) BMD Z-score was -1.9 and she had a 
history of one low impact fracture. On follow-up her Z-score was -2.1 and she 
had sustained another peripheral fracture. The father had osteoporosis (BMD 
T-score -2.5) and the mother was osteopenic. 
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At least one of the parents had osteopenia or osteoporosis in 13 out of 24 inves-
tigated families, while both parents had normal BMD in only six families. This 
indicates heredity of the bone phenotype. Mild OI can easily be mistaken for 
non-OI primary osteoporosis. In our material, 12 patients were found negative 
for mutations in type I collagen upon genetic screening and no patients had 
features of OI. The screened patients did not differ clinically from the patients 
with clinical exclusion of OI. The patients had no features of other known he-
reditary forms of osteoporosis (summarized in the literary review, Table III).
Table XI. Bone health characteristics at presentation in the study subjects and in 
the parents. Bone mineral density (BMD) was measured with DXA at the lumbar 
spine. Subjects named “A” and “B” are affected siblings. N/A, not available.
* Vertebral fractures diagnosed at later follow-up 
** The lumbar spine BMD Z-score was -2.1 at age 8 years.
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Genetic ﬁndings
No disease-causing mutations were found in the screened genes LRP5, LRP6, 
and PTHLH. In LRP5, all discovered sequence variants could be found in public 
databases (Table XII). The minor allele frequency of four polymorphisms (Q89R, 
V667M, N740N, and A1330V) was signiﬁcantly higher in children with primary 
osteoporosis when compared to healthy controls: A1330V (27% in patients vs. 
5% in controls, p>0.0001), Q89R (8% vs. 0.3%, p>0.0001), V667M (12% vs. 1%, 
p>0.0001), and N740N (31% vs. 6%, p>0.0001). The other LRP5 polymorphisms 
(p.Leu20dup, IVS4-4T>C (c.884-4T>C), F549F, E644E, V1119V, and R1188R) oc-
curred at similar frequencies between patients and controls. 
The LRP5 variants, A1330V and V667M, decrease Wnt signaling in vitro (Kiel 
et al., 2007; Urano et al., 2009) and have repeatedly been associated with low 
peak bone mass, reduced BMD, and osteoporotic fractures in adult Caucasians 
(Brixen et al., 2007; Ferrari et al., 2004, 2005; Kiel et al., 2007; Koay et al., 2004; 
Koller et al., 2005; Saarinen et al., 2007; Richards et al., 2008; van Meurs et 
al., 2006, 2008). Each risk allele may affect the BMD by 2-5% (Kiel et al., 2007; 
Urano et al., 2009). N740N has been shown to associate with BMD in children, 
but in Caucasian adults the results have been contradictory (Ferrari et al., 2004; 
Kiel et al., 2007; Koay et al., 2004, 2007). In Asians, Q89R and N740N associ-
ate with low BMD (Koh et al., 2004; Lau et al., 2005, 2006; Urano et al., 2004; 
Zhang et al 2005), but only one study presented an association with A1330V in 
this population (Urano et al., 2009). 
The high frequency of the above mentioned polymorphisms among our patients 
may thus contribute to their skeletal phenotype, especially for e.g. Patient 1A, 
who is homozygous for the minor alleles in A1330V and N740N, and hetero-
zygous for V667M. The other siblings with primary osteoporosis (10A and 10B, 
15A and 15B), on the contrary, carried none of these variations in LRP5.
In LRP6, all discovered polymorphisms (C308C, P448P, V483I, P955P, V1062I, 
and C1270C) were previously known and no difference in frequencies could be 
found between patients and controls. This supports previous ﬁndings of no as-
sociation between variations in LRP6 and BMD (van Meurs et al., 2006, 2008).
The choice of PTHLH as a third candidate gene was mainly based on a murine 
low BMD phenotype which closely resembles that of juvenile primary oste-
oporosis (Miao et al., 2005). No sequence variants in PTHLH were found in the 
study cohort, however.
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Table XII. Genetic variations in LRP5 and LRP6 in patients with juvenile osteoporo-
sis and in controls. Only one individual from each sibling pair has been included. 
The changes noted in bold were signiﬁcantly more common in the patients than 
in control subjects.
*p<0.0001 for comparison between patients and sequenced controls
Nucleotide 
change 
Amino acid 
change dbSNP # Allele frequency (n, %) 
13 patients 171 controls 
LRP5     
(26 alleles) (342 alleles) 
c.58-61dupCTG p.Leu20dup rs72555376 dupCTG: 2 (8%) dupCTG: 43 (13%) 
c.226A>G Q89R rs41494349 G: 2 (8%)* G: 1 (0.3%) 
c.884-4T>C - rs314776 C: 12 (46%) C: 99 (29%) 
c.1647T>C F549F rs545382 C: 1 (4%) C: 16 (5%) 
c.1932G>A E644E rs2277268 A: 1 (4%) A: 18 (5%) 
c.1999G>A V667M rs4988321 A: 3 (12%)* A: 2 (0.6%) 
c.2220C>T N740N rs2306862 T: 8 (31%)* T: 19 (6%) 
c.3357A>G V1119V rs556442 G: 6 (23%) G: 52 (15%) 
c.3564G>A R1188R rs117289001 A: 1 (4%) A: 5 (1%) 
c.3989C>T A1330V rs3736228 T: 7 (27%)* T: 18 (5%) 
24 patients  50 controls  
LRP6     
(52 alleles) (100 alleles) 
c.924T>C C308C rs7978064 C: 2 (4%) C: 5 (5%) 
c.1344C>G P448P rs10082834 G: 1 (2%) G: 6 (6%) 
c.1447G>A V483I rs7975614 A: 1 (2%) A: 1 (1%) 
c.2865C>T P955P rs34143723 T: 1 (2%) C: 0 (0%) 
c.3184A>G I1062V rs2302685 G: 9 (17%) G: 15 (15%) 
c.3810C>T C1270C rs1012672 T: 1 (2%) T: 5 (5%) 

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To conclude: These ﬁndings indicate that children with primary non-OI oste-
oporosis have a variable pattern of age of onset, clinical severity, and inher-
itance. This disease entity is poorly known and the prognosis for untreated 
children varies greatly from complete recovery after puberty to progressive, 
debilitating osteoporosis according to the few reports available (Dent and 
Friedman, 1965; Smith, 1995). Genetic factors are likely to play a major role in 
the pathogenesis since the majority of the patients in the present cohort had 
at least one parent with low BMD. The discovered clustering of LRP5 polymor-
phisms which affect Wnt-signaling may affect osteoporosis phenotypes, possi-
bly in conjunction with polymorphisms in other genes affecting bone turnover. 
The polymorphisms in LRP5 cannot alone, however, explain the osteoporosis 
seen in affected carriers, as the impact of each polymorphism on BMD has been 
estimated to only a few percent (Kiel et al., 2007; Urano et al.,2009). 
The polymorphisms found in LRP6 were not over-represented in affected chil-
dren. There is thus far only one published osteoporosis-causing mutation in 
LRP6, and the phenotype included early-onset coronary disease (Many et al., 
2007). GWAS studies have not found any link between LRP6 polymorphisms 
and BMD, which is in concurrence with the results presented here (van Meurs 
et al., 2006, 2008). 
The choice of a third candidate gene, PTHLH, was based on similarities be-
tween the phenotype seen in the patients and in a mouse model harboring 
a PTHLH mutation (Miao et al., 2005). The protein encoded by PTHLH, PTH-
related peptide (PTHrP) is known to function locally in bone recruiting osteo-
genic cells, promoting bone formation and preventing apoptosis (Miao et al., 
2005), and a promoter polymorphism affecting its receptor, PTHR1, associates 
with variations in BMD and adult height in humans (Scillitani et al., 2006). The 
PTHLH gene has not been implicated in GWAS studies focusing on BMD varia-
tions, nor were sequence variations found in patients in this study. This gene, 
however, remains interesting when screening for mutations in children with 
severe primary osteoporosis, due to that fact that it is extremely evolutionarily 
conserved. Only seven exonic variations with minor allele frequencies below 
1:10000 have been found thus far (UCSC and NHLBI databases); variations can-
not be a common cause of osteoporosis, but it is possible that these can be 
found in some osteoporosis subsets.
RESULTS AND DISCUSSION
65
Study IV 
Clinical and genetic ﬁ ndings in Calvarial doughnut
lesions syndrome
This study focuses on a rare dominantly inherited condition of Calvarial dough-
nut lesions (CDL). The name depicts the circular translucencies surrounded by 
rings of sclerotic bone seen on the skull radiographs of affected patients. Other 
features include osteopenia, frequent peripheral and vertebral fractures, tran-
sient cranial nerve palsies, dental caries, jaw tumors, and deafness. S-ALP is 
often increased. Previous reports dating from 1969-2001 include 29 sporadic 
cases and three families comprising 22 cases (Baumgartner et al., 2001). The 
genetic background of this disorder is unknown. Three affected patients have 
been presented here, from a three-generation non-consanguineous family 
(Figure 12)
Figure 12. Pedigree of the family with Calvarial doughnut lesions. Affected indi-
viduals are marked in black, unaffected in white. 
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Clinical ﬁndings
The index patient is a girl, who was admitted for knee pain at the age of 2 
years. She had no ﬁndings of inﬂammatory joint diseases and her spine ra-
diograph revealed coarse trabeculation consistent with osteopenia. Her skull 
radiograph ﬁndings were normal in infancy. At the age of 3 she was diagnosed 
with congenital glaucoma, which has since been addressed with both surgi-
cal and maximal medical treatments. She has sustained long bone low-impact 
fractures (radius, age 6; femur, age 11). At age 11 her LS BMD Z-score was -1.9 
and she was diagnosed with thoracic VCFs. She has no features of OI: her joint 
laxity, sclerae, teeth, and hearing are normal and she has no Wormian bones. 
Skull radiograph revealed sclerotic lesions around and anterior to the coronary 
suture (Figure 13). Her blood biochemistry was consistent with high turnover 
osteoporosis: S-ALP was high (454-992 U/L, reference range 115-435 U/L) and 
bone turnover markers were increased. All other markers of calcium metabo-
lism were normal. Histomorphometric ﬁndings are presented below. She was 
referred to the Bone Clinic at Helsinki University Central Hospital at age 12. 
Intravenous dinatriumpamidronate was administered from age 13 on reduced 
dosage (1 mg/kg every 3 months) for one year followed by normal dosage (1 
mg/kg on three consecutive days every 4 months) for two more years, after 
which treatment was discontinued. The treatment rendered some improve-
ment to her vertebral changes but only little change in BMD. Bone turnover 
markers normalized during treatment and remained so at the one-year follow-
up after discontinuation of treatment (Table XII). She has not sustained any 
new fractures and the changes in her vertebrae have remained stable. 
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Figure 13. Skull and lumbar spine radiographs of the affected family members; 
changes are indicated with arrows. (1) The index patient has sclerosis around and 
anterior to the coronary suture and a thoracic VCF.  (2) The father’s radiograph 
reveals multiple CDLs. He has no obvious lumbar spine changes. (3) The paternal 
grandmother has generalized irregular hyperostosis of the skull and multiple se-
vere lumbar VCFs.
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Table XIII. Changes in bone mineral density and biochemical bone turnover mark-
ers with dinatriumpamidronate treatment in an adolescent with Calvarial dough-
nut lesions. 
BMD, bone mineral density; WB, whole body P-ALP, plasma alkaline phosphatase, in U/L; 
S-PINP, serum N-terminal peptide of type I procollagen, in μg/L; U-INTP, urinary N-telopeptide 
of type I collagen, in nmol/mmol Cr. areference values calculated based on sex and pubertal 
stage based on published data (Mora et al., 1998)
The father has a history of over 10 fractures to his skull, metacarpal and carpal 
bones, ﬁbula, tibia, ulna, radius, and clavicle since the age of 4 years. At 7 years 
he was diagnosed with multiple thoracic VCFs. He has suffered from transient 
palsies on the left facial nerve at 41 years, to the right at 43 years, and to the 
right oculomotor and trochlear nerves at 49 years. His MRI and CT ﬁndings 
showed no narrowing of cranial nerve canals. He has no features of OI and his 
hearing is normal. His eye pressures are slightly elevated but he needs no glau-
coma medication. Blood biochemistry analyses revealed normal levels of ALP, 
vitamin D, PTH, and Ca.  At age 49 years his LS BMD T-score was -1.6 and CDLs 
were seen on a skull radiograph (Figure 13) 
The paternal grandmother has sustained at least 14 peripheral fractures (hu-
merus, radius, tibia, ﬁbula, clavicle, pubic ramus, ribs) since childhood. She has 
multiple VCFs and diffuse irregular hyperostosis of the skull, but no CDLs. No 
BMD measurement has been performed. She was diagnosed with chronic con-
gestive glaucoma at age 58, she receives medical treatment and has undergone 
bilateral argon laser trabeculoplasty at age 59 and cataract surgeries at 69 and 
73 years of age. In addition, she has been diagnosed with goiter, hyperten-
sion, ischemic heart disease, chronic atrial ﬁbrillation, asthma, and Alzheimer’s 
disease.
	
 	
 	
   ! "" "# 
 	
        	 
 	
	
		
       	 
 	
	
	 
		
       	 
 	
	
	 
		
       	 
 !	"
	

       	 
RESULTS AND DISCUSSION
69
Histomorphometric ﬁndings
Bone histomorphometry was assessed from an iliac crest sample from the index 
patient. The bone tissue was abnormal with thin trabeculae and an increased 
trabecular number. This ﬁnding explains her fracture susceptibility despite 
normal bone volume. There were no signs of ﬁbrosis or sclerosis. Osteoclasts 
were abundant, which is consistent with our patient’s high levels of biochemi-
cal bone turnover markers. Parameters of bone mineralization were normal. 
(Table XIV)
Table XIV. Histomorphometric parameters based on a bone biopsy sample from a 
12-year old girl with Calvarial doughnut lesions. Reference values are presented 
as medians and range based on published pediatric reference data (Glorieux et al., 
2000). Abnormal values are in bold.
Genetic ﬁndings
Collagen I genes COL1A1 and COL1A2 were sequenced from the index patients 
DNA sample due to the high-turnover osteoporosis, which also can be seen in 
collagenopathies. No mutations were discovered. Mutations in LRP5 have been 
linked to both osteoporosis and an eye phenotype. Upon Sanger sequencing 
of all exons of LRP5, no putative disease-causing mutations in could be found 
in the patients DNA sample. The patient was heterozygous for a leucine repeat 
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variant (c.58_60dup /p.Leu20dup), which occurs in about 13% of the Finnish 
population (reference population result presented in Table XIII). The variation 
is not over-represented in cohorts with proneness to fractures. Due to the high 
frequency of the patient’s variation in the general population and its modest 
effect on Wnt signaling, it is unlikely to cause the phenotype presented in our 
pedigree (Chung et al., 2009).  
To conclude: According to these ﬁndings and previous reports, the rare syn-
drome of CDL seems to be of dominant inheritance. The genetic background of 
this disease is still obscure, and no mutations were found in COL1A1, COL1A2, 
and LRP5. In a previous report on one patient with CDL no mutations could 
be found in genes encoding collagen I, III, and V, and the conclusion was that 
CDL could be distinguished from OI by MRI of the skull and collagen analysis 
(Baumgartner et al., 2001). 
The phenotype varies even among family members, which is a common fea-
ture of dominantly inherited diseases. Patients in this study had ﬁndings of 
osteopenia, recurrent peripheral and vertebral fractures in childhood, cranial 
nerve palsies in adulthood, and CDLs / sclerosis of the skull. They had no signs 
of hearing deﬁcit or jaw tumors, as has been presented in earlier case reports, 
and this is the ﬁrst known family with CDLs and glaucoma (Baumgartner et al, 
2001). The reason for this discrepancy in phenotype may be that the causative 
genetic change resides in different genes affecting the same pathway. It is also 
possible that the glaucoma found in our pedigree is due to some other genetic 
defect unconnected to CDL.
The histomorphometric ﬁnding of high turnover osteoporosis in the index pa-
tient is consistent with earlier reports. Biopsy showed no signs of sclerosis or 
ﬁbrous dysplasia, but the skull radiograph indicates that she has local scle-
rotic bone changes. High turnover osteoporosis in iliac crest bone biopsies and 
changes consistent with ﬁbrous dysplasia from skull bone biopsies have been 
reported in patients with CDL, and some patients have had increased bone tis-
sue sclerosis. (Baumgartner et al., 2001; Royen et al., 1974). 
Dinatriumpamidronate was administered cyclically for three years due to the 
high-turnover bone metabolism and VCFs. The patient tolerated the medica-
tion well and achieved normalization of bone markers, some improvement in 
her vertebral changes but only a small amelioration of BMD with medication. 
This is the ﬁrst report on response to bisphosphonates in a patient with CDLs. A 
post-treatment bone biopsy would be of interest to show whether the trabecu-
lar thickness improved with treatment. 
RESULTS AND DISCUSSION
71
6. STUDY LIMITATIONS
Due to the small number of patients in the studies, phenotypes were presented 
in a descriptive manner and statistical analyses on the data were underpow-
ered in most cases. 
In Study I, none of the family members were classiﬁed as “healthy” in the link-
age analysis, as the onset and phenotype of a dominantly inherited disease can 
vary, and most subjects were rather young. This decision reduced the power of 
the two-point analysis and limited the statistical signiﬁcance of the ﬁndings. 
The fact that the probands may have inherited the osteoporosis phenotype 
from either or both parents also complicated the analysis, and it was surprising 
that a genomic region shared by maternal relatives and both probands could 
not be found. The discovery of two putative linkage areas within the pedigree 
also made the study more challenging. Targeted next-generation sequencing 
was performed on three affected individuals only. Whole-exome sequencing of 
all affected individuals would of course have provided better data. The intronic 
and intergenic areas were not sequenced. Exon-ﬂanking intronic regions and 
known CpG areas were screened to identify variations affecting splicing and 
gene expression, but to determine whether intronic variants are disease-caus-
ing the study would need to be complemented, with gene expression analyses 
for example. It can not be excluded that changes within the non-coding areas, 
and not the non-synonymous variations presented, could possibly cause the 
presented phenotype, nor can it be dismissed that some small genomic region 
in between the initial microsatellite markers may possibly contain the disease-
causing variant. Regarding next-generation sequencing, there is always a risk 
of low coverage in certain genomic regions, especially in areas with a high 
content of C and G bases. Results from screened individuals were compared 
in pairs to search for variants which may have been missed in one individual, 
but if the sequencing failed in two or three screened individuals, some variants 
in the targeted regions may have been missed. No functional studies on the 
missense variants identiﬁed in this screening have yet been performed. Future 
analyses on gene function and on larger patient subsets are necessary before 
conclusions regarding a link between these variations and the phenotype can 
be drawn.
Studies II and III contained a selection of patients from international centers. 
These centers provide consultation services to a large population and due to 
geographic issues the patients or their family members were not always availa-
ble for further analyses and sampling. Therefore the choice of methods for ge-
netic analyses after the initial DNA screening had to be made based on sample 
availability in Study II. This difﬁculty also limited the amount of parental DNA 
available for screening in Study III. In Study II, the breakpoints of the deletion 
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in Patient 4 could not be pinpointed despite numerous sequencing attempts. 
The identiﬁcation of the breakpoints could have provided interesting informa-
tion regarding intronic regulatory elements in LRP5.  
In Study IV the investigated family included only three affected family mem-
bers. Only a candidate gene approach could be used, which failed to reveal the 
causative genetic defect in the family. Since CDL is an extremely rare disease, 
it could not be included with other cases in this study. The possibilities for 
genome-wide analyses to identify the causative mutation are further discussed 
in the following chapter.   
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7. GENERAL DISCUSSION AND FUTURE PROSPECTS
Despite the strong genetic background of osteoporosis, GWASs have thus far 
provided limited information regarding signiﬁcant osteoporosis-causing gen-
otypes. Replication rates are low between different studies and the numer-
ous genes and SNPs linked to osteoporosis based on GWASs are estimated to 
contribute to only 1-4% of the variation in population BMD (Lau et al., 2006; 
Styrkarsdottir et al., 2008; Yerges et al., 2009). The approach taken in Study I 
was to focus on families with a high prevalence of severe osteoporosis as to 
enable the pinpointing of signiﬁcant osteoporosis-causing gene mutations. No 
single causative mutation was discovered in affected individuals, but these re-
sults may indicate that the disease seen in this family is of complex inheritance. 
Common genetic variations impact bone strength and a combination of varia-
tions can cause a signiﬁcant bone weakness phenotype. Two genomic regions 
were identiﬁed in this study, in chromosomes 1 and 11, which reached the 
threshold for suggestive linkage. Neither of these areas have previously been 
linked to osteoporosis. Based on the targeted next-generation sequencing, 
three non-synonymous variations in BCAR3, MMP10 and DYNC2H1 were iden-
tiﬁed. Only the variation in BCAR3 was predicted to be deleterious to protein 
function, and this gene has no known link to bone phenotypes thus far. The 
variant identiﬁed in MMP10 has previously been implicated to have a role in 
cartilage and ligament maintenance (Kevorkian et al., 2004; Posthumus et al., 
2011), but the phenotype in our patients does not indicate defective cartilage 
function. Biallelic mutations in DYNC2H1 cause the rare polydactyly-short-rib 
syndrome (Hoey et al., 2011). The encoded protein is involved in the function 
of mechanosensory cilia in the osteocytes, and could be a possible candidate 
gene for further studies. The impact of the identiﬁed variations should be elu-
cidated in future studies.  
In contrast to earlier reports referring to idiopathic juvenile osteoporosis as a 
sporadically occurring disorder, the results of Study III implicate a strong hered-
ity of low BMD phenotypes, since many of the assessed children had at least 
one parent with low BMD (Dent and Friedman, 1965; Smith, 1995). Certain 
common SNPs in LRP5 were also shown to be over-represented in children with 
bone weakness. The results support the impact of common variations in this 
Wnt pathway receptor on bone integrity. Study patients probably carry other 
genetic variations which, in combination with the SNPs in LRP5, induce the 
presented phenotypes, as the SNPs in LRP5 only have modest effects on BMD 
according to earlier studies (Styrkarsdottir et al., 2008). Mutations in LRP5, on 
the other hand, can cause signiﬁcant bone phenotypes, and Study II offered 
the ﬁrst published functional data on splice site mutations in this gene. The 
Wnt pathway affects many aspects of metabolism. There are results linking the 
Wnt pathway to the presence of diabetes, hypercholesterolemia, and vascular 
disease (Saarinen et al., 2009). The patients described here were too young to 
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exhibit such changes, but exploration of this pathway may, in years to come, 
explain the clinically known correlation between osteoporosis and metabolic 
diseases.
In Study IV, the knowledge of the rare CDL syndrome was expanded. No known 
large-scale genetic screening has been performed on patients with CDL previ-
ously. Based on the local ﬁndings of ﬁbrous dysplasia, one putative candidate 
gene could be GNAS, which encodes the stimulatory G-protein α-subunit of the 
G-protein complex. Activating mutations in GNAS are known to cause McCune-
Albright syndrome and ﬁbrous dysplasia (Lee et al., 2012). If a candidate gene 
screening failed to identify putative mutations, genome-wide screening meth-
ods could be applied for mutation identiﬁcation. As this disease seems to be 
of monogenic inheritance, microsatellite linkage analysis would be the logical 
method of choice. This would require international collaboration, since this 
study pedigree is too small and hitherto published cases are scarce. There is 
also the risk that separate pedigrees carry mutations in different genes of a 
mutual pathway, which would render the use of linkage analysis more com-
plicated. Whole-exome sequencing would identify putative disease-causing 
exonic changes, but since the disease is suspected to be of heterozygous in-
heritance, sorting the large amount of data achieved by this approach would 
cause signiﬁcant challenges (Ng et al., 2008). Another approach would be gene 
expression analyses, preferably from material derived from patients’ skeletal 
tissue. Based on our small pedigree, the search would be truly challenging us-
ing currently available screening methods.
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8. CONCLUSIONS
Genetic variation (SNPs) in LRP5 affects bone health already in child-
hood and adolescence. LRP5 and possibly other genes involved in the 
Wnt-signalling pathway are likely to have a major role in bone mass 
development and maintenance of skeletal integrity from early child-
hood. Screening for harmful sequence variations in these genes may 
provide a tool for early detection of individuals with an increased 
risk for symptomatic osteoporosis. Such markers would be helpful in 
optimal targeting of preventive measures.  
CDL is not caused by mutations in COL1A1, COL1A2, or LRP5. The dis-
order thus represents a distinctive form of dominantly inherited pri-
mary osteoporosis. The histomorphometric ﬁndings are characterized 
by increased bone turnover. Identiﬁcation of the causative genetic 
defect requires a next-generation sequencing approach of larger co-
horts of affected individuals but would be valuable in understanding 
the pathophysiology of CDL and more widely, the pathogenesis of 
high-turnover osteoporosis.
We present a new form of inherited early-onset osteoporosis in a 
large Finnish family. Despite apparent autosomal dominant inherit-
ance and an inheritance pattern similar to monogenic diseases, no 
genetic defect common to all affected subjects could be identiﬁed. 
Dominantly inherited diseases have reduced penetrance and this may 
have affected our analyses. Our ﬁndings indicate that genetic factors 
play a major role in primary osteoporosis and early clinical and radio-
graphic screening of potentially affected individuals is recommended 
for early intervention to prevent severe spinal complications. 
Variations in BCAR3, MMP10, or DYNC2H1 may contribute to bone 
weakness phenotypes. The role of these genes and the functional 
implications of the identiﬁed sequence variations need to be further 
elucidated in future studies. 
The search for new osteoporosis-causing genes is of importance, as the dis-
coveries help to resolve the mechanisms causing the molecular and cellular 
pathogenesis of the disease. The ﬁndings may aid in the development of new 
therapeutic agents - as was the case with denosumab, which is a monoclonal 
antibody which binds to RANKL thereby hindering osteoclast proliferation and 
bone resorption (Cummings et al., 2009). The signiﬁcance of the Wnt pathway 
in bone building was unveiled by the identiﬁcation of mutations in LRP5 by 
linkage analysis in patients with high and low BMD phenotypes (Gong et al., 
2001; Little et al., 2001). The use of lithium, an old and well-known drug for bi-
1.
2.
3.
4.
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polar disorder, is now investigated as an osteoporosis treatment due to its abil-
ity to activate the Wnt pathway (Mosekilde et al., 2011). The other advantage 
of new genetic ﬁndings is the possibility to screen patients at risk for genomic 
variations. As our knowledge regarding the clinical impact of these variations 
increases, genetic screening may become a tool for early patient identiﬁcation, 
prevention, and targeting of treatments.  
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